Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 16394. Отображено 100.
05-01-2012 дата публикации

Clathrate, curing agent, cure accelerator, epoxy resin composition, and epoxy resin composition for encapsulation of semiconductor

Номер: US20120004377A1
Автор: Kazuo Ono, Masami Kaneko
Принадлежит: Nippon Soda Co Ltd

It is an object of the present invention to provide a clathrate that suppresses a curing reaction at low temperature to promote an improvement in storage stability (one-component stability), and can effectively cure a resin by heating treatment. A clathrate suitable for the clathrate is a clathrate containing (b1) at least one selected from the group consisting of an aliphatic polyvalent carboxylic acid, 5-nitroisophthalic acid, 5-tert-butylisophthalic acid, 5-hydroxyisophthalic acid, isophthalic acid, and benzophenone-4,4′-dicarboxylic acid; and (b2) at least one selected from the group consisting of an imidazole compound represented by the following formula (I), and 1,8-diazabicyclo[5.4.0]undecene-7, at a molar ratio of 1:1.

Подробнее
Номер записи: 1
26-01-2012 дата публикации

Fluorine-containing n-alkylsulfonylimide compound, manufacturing method therefor, and method of manufacturing an ionic compound

Номер: US20120022269A1
Автор: Daisuke Takano, Hiroyuki Yatsuyanagi, Takashi Konishi, Tsunetoshi Honda
Принадлежит: Mitsubishi Materials Corp, Mitsubishi Materials Electronic Chemicals Co Ltd

According to the method for producing fluorine-containing N-alkylsulfonylimide compound, the fluorine-containing N-alkylsulfonylimide compound can be produced safely with a high recovery rate by alkylating fluorine-containing sulfonylimide acid or fluorine-containing sulfonylimide acid salt with dialkylsulfuric acid or dialkylcarbonic acid.

Подробнее
Номер записи: 2
09-02-2012 дата публикации

Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

Номер: US20120035230A1
Автор: Alan D. Snow, F. Michael Hudson, Joel Cummings, Luke A. Esposito, Manfred Weigele, Thomas Lake
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
Номер записи: 3
09-02-2012 дата публикации

Volatile Imidazoles and Group 2 Imidazole Based Metal Precursors

Номер: US20120035351A1
Автор: John Anthony Thomas Norman, Melanie K. Perez, Moo-Sung Kim
Принадлежит: Air Products and Chemicals Inc

Sterically hindered imidazole ligands are described, along with their synthesis, which are capable of coordinating to Group 2 metals, such as: calcium, magnesium, strontium, in an eta-5 coordination mode which permits the formation of monomeric or dimeric volatile complexes. A compound comprising one or more polysubstituted imidazolate anions coordinated to a metal selected from the group consisting of barium, strontium, magnesium, radium or calcium or mixtures thereof. Alternatively, one anion can be substituted with and a second non-imidazolate anion. Synthesis of the novel compounds and their use to form BST films is also contemplated

Подробнее
Номер записи: 4
19-04-2012 дата публикации

Ionic liquid solvents of perhalide type for metals and metal compounds

Номер: US20120090430A1
Автор: John Holbrey, Robin Don Rogers
Принадлежит: Individual

The present invention relates to a process for dissolving metals in perhalide containing ionic liquids, and to the extraction of metals from mineral ores; the remediation of materials contaminated with heavy, toxic or radioactive metals; and to the removal of heavy and toxic metals from hydrocarbon streams.

Подробнее
Номер записи: 5
26-04-2012 дата публикации

Compositions and articles comprising polymerizable ionic liquid mixture, and methods of curing

Номер: US20120101184A1
Автор: Brian N. Holmes, Joel D. Oxman, Joseph D. Rule, Kevin M. Lewandowski, Larry R. Krepski, Peiwang Zhu, Richard L. Severance, Thomas P. Klun, Yizhong Wang
Принадлежит: 3M Innovative Properties Co

Presently described are curable compositions comprising a mixture of at least one (e.g. free-radically) polymerizable ionic liquid and at least one other ethylenically unsaturated monomer, oligomer, or polymer. The polymerizable ionic liquid is characterized as having an air to nitrogen curing exotherm ratio of at least 0.70. Also described are articles and methods of making articles from such curable compositions. A monofunctional polymerizable ionic liquid is also described comprising a non-polymerizable substituted imidazolium cationic group and a polymerizable sulfonate anion.

Подробнее
Номер записи: 6
17-05-2012 дата публикации

Process for the preparation of strontium ranelate

Номер: US20120123131A1
Автор: Kapil Ramesh Hire, Koilpillai Joseph Prabahar, Prashant Bhaskarrao Patil, Pravin Bhalchandra Kulkarni
Принадлежит: Individual

The present invention relates to an improved process for the synthesis of strontium ranelate or hydrates thereof. More particularly, the present invention relates to an effective process for the preparation of a compound of formula III, which is a useful intermediate in the synthesis of strontium ranelate. wherein R 1 and R 2 represents substituted or unsubstituted linear or branched C 1 -C 6 alkyl group or C 3 -C 12 cyclic group.

Подробнее
Номер записи: 7
23-08-2012 дата публикации

High Stability Diionic Liquid Salts

Номер: US20120215005A1
Автор: Daniel W. Armstrong, Jared Anderson
Принадлежит: Sigma Aldrich Co LLC

The present invention relates to diionic liquid salts of dicationic or dianionic molecules, as well as solvents comprising diionic liquids and the use of diionic liquids as the stationary phase in a gas chromatographic column.

Подробнее
Номер записи: 8
13-09-2012 дата публикации

Methods of treating emesis using growth hormone secretagogues

Номер: US20120232113A1
Автор: William J. Polvino, William R. Mann
Принадлежит: Helsinn Therapeutics Us Inc

The present invention relates to methods of treating or preventing emesis and improving a subject's ASAS score by administering to the subject an effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.

Подробнее
Номер записи: 9
04-10-2012 дата публикации

Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies

Номер: US20120252858A1
Автор: Alan D. Snow, F. Michael Hudson, Joel Cummings, Lesley Larsen, Luke A. Esposito, Manfred Weigele, Thomas Lake
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
Номер записи: 10
06-12-2012 дата публикации

Process for the preparation of perfluoroalkylcyano- or perfluoroalkylcyanofluoroborates

Номер: US20120309981A1
Автор: Jan Sprenger, Maik Finze, Michael Schulte, Nikolai (Mykola) Ignatyev, Walter Frank
Принадлежит: Merck Patent GmBH

The invention relates to a process for the preparation of salts having perfluoroalkyltricyano- or perfluoroalkylcyanofluoroborate anions, ((per)fluoro)phenyltricyano- or ((per)fluoro)phenylcyanofluoroborate anions, phenyltricyanoborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms or phenylcyanofluoroborate anions which are mono- or disubstituted by perfluoroalkyl groups having 1 to 4 C atoms, by reaction of alkali metal trifluoroperfluoroalkylborate with trialkylsilyl cyanide and a subsequent salt-exchange reaction or by direct reaction of an organic trifluoroperfluoroalkyl borate with trialkylsilyl cyanide.

Подробнее
Номер записи: 11
30-05-2013 дата публикации

COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER

Номер: US20130137740A1
Автор: Biersack Bernhard, Müller Thomas, Schobert Rainer
Принадлежит:

The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer. 2. The compound of claim 1 , wherein Ris selected from —Cl claim 1 , —Br claim 1 , or —NH.3. The compound of claim 1 , wherein Ris selected from hydrogen claim 1 , halogen claim 1 , —OH claim 1 , or —NH.4. The compound of claim 1 , wherein Ris selected from —O—CH claim 1 , —O—CH—CH claim 1 , or —N(CH).5. The compound of claim 1 , wherein Ris selected from —O—CHor —N(CH).6. The compound of claim 1 , wherein Rand Rjointly form a group —C(Cl)═CH—N(CH)—.7. The compound of claim 1 , wherein X is selected from O and N(CH).8. The compound of claim 1 , wherein the compound is selected from 1-methyl-5-(3-amino-4-methoxyphenyl)-4-(3-chloro-4 claim 1 ,5-dimethoxyphenyl)-imidazole claim 1 , 1-methyl-5-(3-amino-4-methoxyphenyl)-4-(3-bromo-4 claim 1 ,5-dimethoxyphenyl)-imidazole claim 1 , 1-methyl-5-(3-amino-4-ethoxyphenyl)-4-(3-chloro-4 claim 1 ,5-dimethoxyphenyl)-imidazole or 1-methyl-5-(3-amino-4-ethoxyphenyl)-4-(3-bromo-4 claim 1 ,5-dimethoxyphenyl)-imidazole claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof.9. The compound of claim 1 , wherein the compound is selected from 1-methyl-4-(3-chloro-4 claim 1 ,5-dimethoxyphenyl)-5-(3-fluoro-4-ethoxyphenyl)-imidazole or 1-methyl-4-(3-bromo-4 claim 1 ,5-dimethoxyphenyl)-5-(3-fluoro-4-ethoxyphenyl)-imidazole claim 1 , or a pharmaceutically acceptable salt claim 1 , solvate claim 1 , or prodrug thereof.10. The compound of claim 1 , wherein the compound is selected from 1-methyl-4-(3-amino-4 claim 1 ,5-dimethoxyphenyl)-5-(N-methyl-3-chloroindol-5-yl)-imidazole claim 1 , 1-methyl-4-(3-chloro-4 claim 1 ,5-dimethoxyphenyl)-5-(N-methyl-3-chloroindol-5-yl)-imidazole or 1- ...

Подробнее
Номер записи: 12
29-08-2013 дата публикации

PROCESS FOR THE RESOLUTION OF MEDETOMIDINE AND RECOVERY OF THE UNWANTED ENANTIOMER

Номер: US20130225832A1
Автор: "ZACCHE Matteo", Gatti Pier Andrea, GERLI Fulvio
Принадлежит: EDMOND PHARMA s.r.l.

A new and efficient process to obtain Medetomidine enantiomers, a selective and potent α2-receptor agonist, is presented. Such process comprises a resolution step and a racemisation reaction, to be able to recover the unwanted enantiomer which can be recycled as starting material. 1. A process for a resolution of Medetomidine enantiomers comprising:a) preparing a solution of Medetomidine base in a suitable solvent or solvent mixture;b) adding the solution with of half a mole of an enantiomerically pure carboxylic acid;c) optionally heating the solution and then cooling it until complete precipitation of a desired enantiomer as a salt;d) purifying the desired salt by treatment with a suitable solvent, optionally under heating;e) isolating the desired salt and converting it to the free base with methods known in the art.2. A process according to further comprising recycling the undesired enantiomer with the following steps:f) treating a mother liquors from step c) with a radical initiator, optionally in the presence of light as activator;g) isolating a racemic material and recycling it to step a).3. A process according to wherein the desired enantiomer is the S-enantiomer.4. A process according to wherein the enantiomerically pure acid is selected from malic acid claim 1 , camphorsulfonic acid claim 1 , tartaric acid claim 1 , dibenzoyltartaric acid claim 1 , ditoluyltartaric acid claim 1 , pivaloyltartaric acid.5. A process according to wherein the acid is (+)-malic acid.6. A process according to wherein the solvent of step a) is a straight alcohol.7. A process according to wherein the alcohol is dry or hydrate methanol or ethanol. This non-provisional application claims priority to and the benefit of Italian Application No. MI2012A000311 filed on Feb. 29, 2012, the content of which is incorporated herein by reference in its entirety.The present invention relates to a process for the resolution of Medetomidine enantiomers.Medetomidine of formula 1is a potent, ...

Подробнее
Номер записи: 13
19-09-2013 дата публикации

BENZIMIDAZOLE DERIVATIVES USEFUL AS TRPM8 CHANNEL MODULATORS

Номер: US20130245085A1
Автор: Macielag Mark J., Xia Mingde, XU Xiaoqing
Принадлежит: Janssen Pharmaceutica, NV

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: 18-. (canceled)11. A method as in claim 10 , wherein the inflammatory pain is due to inflammatory bowel disease claim 10 , visceral pain claim 10 , migraine claim 10 , post operative pain claim 10 , osteoarthritis claim 10 , rheumatoid arthritis claim 10 , back pain claim 10 , lower back pain claim 10 , joint pain claim 10 , abdominal pain claim 10 , chest pain claim 10 , labor claim 10 , musculoskeletal diseases claim 10 , skin diseases claim 10 , toothache claim 10 , pyresis claim 10 , burn claim 10 , sunburn claim 10 , snake bite claim 10 , venomous snake bite claim 10 , spider bite claim 10 , insect sting claim 10 , neurogenic bladder claim 10 , interstitial cystitis claim 10 , urinary tract infection claim 10 , rhinitis claim 10 , contact dermatitis/hypersensitivity claim 10 , itch claim 10 , eczema claim 10 , pharyngitis claim 10 , mucositis claim 10 , enteritis claim 10 , irritable bowel syndrome claim 10 , cholecystitis claim 10 , pancreatitis claim 10 , postmastectomy pain syndrome claim 10 , menstrual pain claim 10 , endometriosis claim 10 , sinus headache claim 10 , tension headache claim 10 , or arachnoiditis.12. A method as in claim 10 , wherein the inflammatory pain is inflammatory hyperalgesia.13. A method as in claim 12 , wherein the inflammatory hyperalgesia is inflammatory somatic hyperalgesia or inflammatory visceral hyperalgesia.14. A method as in claim 12 , wherein the inflammatory hyperalgesia is due to inflammation claim 12 , osteoarthritis claim 12 , rheumatoid arthritis claim 12 , back pain claim 12 , joint pain claim 12 , abdominal pain claim 12 , musculoskeletal diseases claim 12 , skin diseases claim 12 , post operative pain claim 12 , headaches claim 12 , fibromyalgia claim 12 , toothache claim 12 , burn claim 12 , sunburn claim 12 , insect sting ...

Подробнее
Номер записи: 14
19-09-2013 дата публикации

Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives

Номер: US20130245274A1
Автор: BOEHM Claudius, KLEIN Susanne, NAPIERSKI Bernard, SOMMER Christian
Принадлежит: SANOFI

The present invention relates to a process for the preparation of a compound of the formula I, 2. The process as claimed in claim 1 , wherein the compound of formula I is prepared whereA2 is aminopyridyl, in which aminopyridyl is unsubstituted or substituted independently of one another once, twice or three times by halogen or methyl;{'sub': 3', '8, 'claim-text': where R1 is', {'sub': 1', '4, 'a) phenyl, where phenyl is unsubstituted or substituted once, twice or three times independently of one another by —(C-C) alkyl,'}, 'b) halogen,', {'sub': 1', '4, 'c) —(C-C)-alkyl,'}, {'sub': 3', '6, 'd) —(C-C)-cycloalkyl,'}, {'sub': '3', 'e) —CF,'}, {'sub': '3', 'f) —O—CF,'}, 'g) triazolyl or', 'h) pyridinyl;, 'Y is —(C-C)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times by R1,'}R15 is an amino protecting group selected from tert-butyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzylcarbonyl, N-formyl, N-acetyl, N-benzyl, N-1-(diphenyl)methyl, N-trityl, (4-methoxyphenyl)diphenylmethyl, N-dialkyl phosphoramidates and N-p-toluenesulfonyl; and{'sub': 1', '6, 'claim-text': [{'sub': 1', '6, '2) —(C-C)-alkyl-OH,'}, {'sub': 1', '4', '3', '6, '3) —(C-C)-alkylene-(C-C)-cycloalkyl or'}, {'sub': 1', '10', '3', '6, '4) —(C-C)-alkylene-O—C(O)—O—(C-C)-cycloalkyl.'}], 'Z is 1) —(C-C)-alkyl,'}3. The process as claimed in claim 1 , wherein the compound of formula I is prepared whereA2 is 2-aminopyridyl,R15 is tert-butyloxycarbonyl,{'sub': 3', '8, 'Y is —(C-C)-cycloalkyl, which is unsubstituted or substituted by one or two methyl and'}{'sub': 1', '4, 'Z is —(C-C)-alkyl.'}5. The compound of formula I as claimed in claim 4 , whereinA2 is aminopyridyl, in which aminopyridyl is unsubstituted or substituted independently of one another once, twice or three times by halogen or methyl;{'sub': 3', '8, 'Y is —(C-C)-cycloalkyl, in which cycloalkyl is unsubstituted or substituted independently of one another once, twice or three times ...

Подробнее
Номер записи: 15
17-10-2013 дата публикации

IMIDAZOLE COMPOUND PRODUCTION METHOD, IMIDAZOLE COMPOUND, IMIDAZOLE-BASED COMPOUND, ORGANIC METAL COMPLEX, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE

Номер: US20130270541A1
Автор: Numata Masaki
Принадлежит: IDEMITSU KOSAN CO., LTD.

A manufacturing method of an imidazole compound represented by a formula (1) below includes reacting 1-arylimidazole with a halogen-atom substituted compound. For performing this reaction, in a reaction system, a mole number N[mol] of the halogen-atom substituted compound and a total volume V[liter] of an ether solvent having at most 5 carbon atoms satisfy a relationship of V/N≦3. 2. The manufacturing method of the imidazole compound according to claim 1 , wherein{'sub': f2', 'A, 'claim-text': {'br': None, 'i': V', '/N, 'sub': A', 'f2, '≦2\u2003\u2003(2).'}, 'the mole number Nof the compound represented by the formula (2) and the total volume Vsatisfy a relationship of a numerical formula (2) below,'}3. The manufacturing method of the imidazole compound according to claim 1 , wherein{'sub': f2', 'A, 'claim-text': {'br': None, 'i': V', '/N, 'sub': A', 'f2, '≦1\u2003\u2003(3).'}, 'the mole number Nof the compound represented by the formula (2) and the total volume Vsatisfy a relationship of a numerical formula (3) below,'}4. The manufacturing method of the imidazole compound according to claim 1 , whereinthe ether solvent comprising at most 5 carbon atoms is at least one ether solvent selected from tetrahydrofuran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, diethylether and 1,2-dimethoxyethane.5. The manufacturing method of the imidazole compound according to claim 1 , further comprising:{'sub': f2', 'A, 'implementing a solvent removal treatment of removing the solvent in the reaction system to adjust the relationship between the mole number Nand the total volume V.'}6. The manufacturing method of the imidazole compound according to claim 1 , whereinas a second solvent, at least one solvent selected from an aliphatic hydrocarbon solvent comprising at least 7 carbon atoms, an aromatic hydrocarbon solvent and an ether solvent comprising at least 6 carbon atoms is contained in the reaction system, and{'sub': f2', 'B, 'claim-text': {'br': None, 'b': 0', '1, 'i': V', '/N, ...

Подробнее
Номер записи: 16
07-11-2013 дата публикации

Polymer

Номер: US20130295040A1
Автор: Adam Peter Jarvis, Adrian Carmichael, Andrew Gregory Steward, David M. Haddleton, François LECOLLEY, Giuseppe Mantovani, Lei Tao
Принадлежит: Warwick Effect Polymers Limited

The application provides a method of producing a comb polymer comprising the steps of: (a) Providing: (i) a plurality of monomers which are linear, branched or star-shaped, substituted or non-substituted, and have an olefinically unsaturated moiety, the olefinically unsaturated moiety being capable of undergoing addition polymerisation; (ii) an initiator compound; the initiator compound comprising a homolytically cleavable bond. (iii) a catalyst capable of catalysing the polymerisation of the monomer; and (b) Causing the catalyst to catalyse, in combination with the initiator, the polymerisation of a plurality of the monomers to produce the comb polymer. Catalysts and polymers obtainable by the process are also provided. Preferably, the comb polymer is capable of binding proteins and may be produced from monomers which are alkoxy polyethers, such as poly(alkyleneglycol) or polytetrahydrofuran.

Подробнее
Номер записи: 17
07-11-2013 дата публикации

Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions

Номер: US20130296346A1
Автор: Ana Munoz Munoz, Antonio De La Hera Martinez, Beatriz Lopez Ortega, Francisco Ledo Gomez, Melchor Alvarez De Mon Soto, Neftali Garcia Dominguez, Rosa Rodes Solanes
Принадлежит: Faes Farma SA

The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.

Подробнее
Номер записи: 18
26-12-2013 дата публикации

2,4- diaminopyrimidine derivatives

Номер: US20130345180A1
Автор: Anette Von Matt, Christos Papageorgiou, Gebhard Thoma, Gerhard Zenke, Ichiro Umemura, Kazuhiko Nonomura, Klaus Hinterding, Naoko Matsuura, Nigel Graham Cooke, Osamu Ohmori, Rolf Baenteli, Rudolf Duthaler, Toshiyuki Honda
Принадлежит: NOVARTIS AG

There are provided compounds of formula I wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as indicated in claim 1 , useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Подробнее
Номер записи: 19
23-01-2014 дата публикации

SULFONAMIDE DERIVATIVE AND USE THEREOF

Номер: US20140024650A1
Автор: ASANO Yasutomi, Fukuda Koichiro, Fukumoto Shoji, IMAEDA Toshihiro, Iwanaga Kouichi, KORI Masakuni, Mikami Satoshi, Morimoto Shinji, Nakamura Shinji, Tokunaga Norihito, Ujikawa Osamu
Принадлежит: Takeda Pharmaceutical Company Limited

Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. A compound represented by the formula (I): 2. The compound according to claim 1 , wherein ring A is{'sub': '3-6', 'optionally further substituted Ccycloalkane,'}an optionally further substituted tetrahydrofuran ring,an optionally further substituted tetrahydropyran ring,an optionally further substituted piperidine ring,an optionally further substituted tetrahydrothiopyran ring oran optionally further substituted 8-oxabicyclo[3.2.1]octane ring,or a salt thereof.3. The compound according to claim 1 , wherein the substituent(s) on the ring A is(are) selected from(1) 1 to 3 halogen atoms,{'sub': '1-6', '(2) a Calkyl group optionally substituted by one phenyl group,'}{'sub': '1-6', '(3) a carbamoyl group substituted by a Calkyl group,'}{'sub': '1-6', '(4) a Calkyl-carbonyl group,'}{'sub': '1-6', '(5) a Calkoxy-carbonyl group,'}(6) an oxo group,(7) a hydroxyl group and{'sub': '1-6', '(8) a Calkylsulfonyl group,'}or a salt thereof.5. The compound according to claim 1 , wherein ring B is a benzene ring claim 1 , or a salt thereof.6. The compound according to claim 1 , wherein the substituent on the ring B is selected from(1) a halogen atom;(2) a cyano group;{'sub': '1-6', '(3) a Calkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a cyano group;'}{'sub': '1-6', '(4) a hydroxyl group optionally substituted by a Calkyl group optionally substituted by 1 to 3 halogen atoms or a phenyl group (including alkoxy);'}{'sub': 1-6', '1-6, '(5) an amino group optionally substituted by 1 or 2 substituents selected from a Calkyl group, a Calkyl-carbonyl and a phenyl group;'}{'sub': '3-6', '(6) a Ccycloalkyl group;'}(7) a tricyclo[3.3.1.1.3.7]decyl group;(8) phenyl optionally substituted by 1 to 3 substituents selected ...

Подробнее
Номер записи: 20
30-01-2014 дата публикации

Ligands for imaging cardiac innervation

Номер: US20140030189A1
Автор: Ajay Purohit, David S. Casebier, Heike S. Radeke, Michael T. Azure, Ming Yu, Simon P. Robinson, Thomas D. Harris
Принадлежит: ACP Lantern Acquisition Inc, Bristol Myers Squibb Pharma Co, Lantheus Medical Imaging Inc

Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

Подробнее
Номер записи: 21
10-04-2014 дата публикации

PRINTED ENERGY STORAGE DEVICE

Номер: US20140099528A1
Автор: Gustafson John G., Hartman Alexandra E., Lockett Vera N., Lowenthal Mark D., Ray William J.
Принадлежит: NthDegree Technologies Worldwide, Inc.

A printed energy storage device includes a first electrode including zinc, a second electrode including manganese dioxide, and a separator between the first electrode and the second electrode, the first electrode, second, electrode, and separator printed onto a substrate. The device may include a first current collector and/or a second current collector printed onto the substrate. The energy storage device may include a printed intermediate layer between the separator and the first electrode. The first electrode, and the second electrode may include 1-ethyl-3-methylimidazolium tetrafluoroborate (CmimBF). The first electrode and the second electrode may include an electrolyte having zinc tetrafluoroborate (ZnBF) and 1-ethyl-3-methylimidazolium tetrafluoroborate (CmimBF). The first electrode, the second electrode, the first current collector, and/or the second current collector can include carbon nanotubes. The separator may include solid microspheres. 1. A printed energy storage device comprising:a first electrode;a second electrode; anda separator positioned between the first electrode and the second electrode, at least one of the first electrode and the second electrode comprising an ionic liquid,wherein the ionic liquid includes a cation selected from the group consisting of 1-ethyl-3-methylimidazolium, butyltrimethylammonium, 1-butyl-3-methylimidazolium, 1-methyl-3-propylimidazolium, 1-hexyl-3-methylimidazolium, choline, ethylammonium, tributylmethylphosphonium, tributyl(tetradecyl)phosphonium, trihexyl(tetradecyl)phosphonium, 1-ethyl-2,3-methylimidazolium, 1-butyl-1-methylpiperidinium, diethylmethylsulfonium, 1-methyl-3-propylimidazolium, 1-methyl-1-propylpiperidinium, 1-butyl-2-methylpyridinium, 1-butyl-4-methylpyridinium, 1-butyl-1-methylpyrrolidinium, and diethylmethylsulfonium, andwherein the ionic liquid includes an anion selected from the group consisting of tetrafluoroborate, tris(pentafluoroethyl)trifluorophosphate, trifluoromethanesulfonate, ...

Подробнее
Номер записи: 22
06-01-2022 дата публикации

METHOD FOR PRODUCING TRIARYLORGANOBORATES

Номер: US20220002321A1
Автор: Berneth Horst, Bruder Friedrich-Karl, Hönel Dennis, Kintrup Jürgen, Rölle Thomas
Принадлежит:

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms. 1. Process for preparing triaryl organoborates of the formula 1/n KRB—R(IV) , where one equivalent of organoboronic ester of the formula B—R(OR)(OR) (I) is initially charged together with 1/n equivalents of salt K nX (II) and 3 equivalents of metal M in a solvent or a solvent mixture S1 , 3 equivalents of a haloaromatic R—Y (III) are added , an auxiliary L and optionally a second organic solvent or solvent mixture S2 is added and the compound 1/n K RB—R(IV) is separated off with the organic phase and{'sup': '1', 'sub': 1', '22', '3', '22', '3', '22', '5', '7', '7', '13, 'Ris an optionally hydroxyl- and/or alkoxy- and/or acyloxy- and/or halogen-substituted C- to C-alkyl, C- to C-alkenyl, C- to C-alkynyl, C- to C-cycloalkyl or C- to C-aralkyl radical,'}{'sup': 2', '3', '2', '3, 'sub': 1', '22', '3', '7, 'Rand Rare independently an optionally branched C- to C-alkyl radical or an optionally alkyl-substituted C- to C-cycloalkyl radical or Rand Rtogether form a 2-8-membered carbon bridge which is optionally substituted by alkyl and/or interrupted by oxygen atoms,'}{'sup': '4', 'sub': 6', '10', '1', '4', '1', '4, 'Ris a C- to C-aryl radical optionally substituted by at least one radical selected from halogen, C- to C-alkyl, trifluoromethyl, C- to C-alkoxy, trifluoromethoxy, phenyl and phenoxy,'}K is an organocation of valency n and having any substitution, based on nitrogen, phosphorus, oxygen, sulfur and/or iodine, and{'sup': 2', '3, 'L is an auxiliary that forms a complex of sparing solubility in S1 and/or S2 with M salts MY(OR), MY(OR) and MXY, where L is a Lewis-basic compound, especially selected from the group consisting of open chain ...

Подробнее
Номер записи: 23
05-01-2017 дата публикации

CIT-10: A TWO DIMENSIONAL LAYERED CRYSTALLINE MICROPOROUS SILICATE COMPOSITION AND COMPOSITIONS DERIVED THEREFROM

Номер: US20170001872A1
Автор: Davis Mark E., SCHMIDT JOEL E.
Принадлежит:

This disclosure relates to a new crystalline microporous silicate solid, designated CIT-10, comprising a two dimensional layered structure, having an organic interlayer sandwiched between individual crystalline silicate layers. This CIT-10 material can be converted to a pure-silicate of RTH topology, as well as two new of pillared silicate structures, designated CIT-11 and CIT-12. This disclosure characterizes new materials and provides methods of preparing and using these new crystalline microporous solids. 1. A crystalline microporous silicate , designated CIT-10 , which exhibits a powder X-ray diffraction (XRD) pattern exhibiting at least five of the characteristic peaks at 7.6±0.2° , 8.7±0.2° , 10.3±0.2° , 18.8±0.2° , 20.3±0.2° , 21.8±0.2° , 22.4±0.2° , 22.7±0.2° , 22.9±0.2° , and 23.6±0.2° 2-theta.2. The crystalline microporous silicate of claim 1 , wherein the crystalline microporous silicate comprises a two dimensional layered structure claim 1 , having an organic material sandwiched between individual crystalline silicate layers.3. The crystalline microporous silicate of claim 2 , having a structure which is ordered along its two dimensional crystalline silicate layers claim 2 , but which exhibits disorder between its crystalline silicate layers claim 2 , as evidenced by RED (rotating electron diffraction) structure analysis.4. The crystalline microporous silicate of claim 1 , which exhibits an Si-MAS NMR spectrum having resonances at chemical shifts of −113 ppm claim 1 , −107 ppm claim 1 , and −102 ppm claim 1 , relative to tetramethylsilane (TMS).5. The crystalline microporous silicate of claim 4 , wherein the resonances at chemical shifts of −113 ppm claim 4 , −107 ppm claim 4 , and −102 ppm have relative integrated intensities of 8 claim 4 , 5 claim 4 , and 3 claim 4 , respectively.7. A crystalline microporous silicate claim 4 , designated CIT-11 claim 4 , which exhibits a powder X-ray diffraction (XRD) pattern exhibiting at least five of the ...

Подробнее
Номер записи: 24
04-01-2018 дата публикации

PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES

Номер: US20180002292A1
Автор: BERTOGG Andreas, SCHILLING Hanspeter
Принадлежит:

The present invention relates to a process for providing the compound of formula I, comprising the step of reacting a compound of formula VII with a base in the presence of an alkaline- or alkaline earth metal salt (MX), wherein LG is a leaving group. The presence of an alkaline- or alkaline earth metal salt was surprisingly found to render said reaction highly reliable in terms of the yield and purity of the compound of formula I obtained. In a further aspect, the present invention relates to the compound of formula I, having less than an amount of 1.50% or less than an amount of 1.25% or less than an amount of 1.00% or less than an amount of 0.75% or less than an amount of 0.50% or less than an amount of 0.25% or less than an amount of 0.10% of the compound of formula VIII. 3. The process according to claim 1 , further comprising one step of converting the compound of formula (I) claim 1 , the compound of formula (Ia) or the compound of formula (Ib) to a pharmaceutically acceptable salt thereof.4. The process according to claim 3 , wherein the pharmaceutically acceptable salt is a monophosphate salt.5. (canceled)6. (canceled)7. (canceled)8. The process according to claim 1 , wherein the base is selected from the group consisting of1. an alkaline- or alkaline earth metal amide;2. an alkaline- or alkaline earth metalalkoxide;3. an alkaline- or alkaline earth metal hydride;4. an organolithium reagent; and5. an organomagnesium reagent.9. (canceled)10. (canceled)11. The process according to claim 8 , wherein the alkaline- or alkaline earth metal amide is lithium bis(trimethylsilyl)amide.12. The process according to claim 1 , wherein the leaving group is a halogenide claim 1 , a hydroxyl group activated through esterification or cyanide.13. (canceled)14. (canceled)15. The process according to claim 12 , wherein the leaving group is chloride.16. (canceled)17. The process according to claim 1 , wherein the alkaline- or alkaline earth metal salt is a lithium salt claim 1 , ...

Подробнее
Номер записи: 25
03-01-2019 дата публикации

13-Cis-RAMBA RETINAMIDES THAT DEGRADE MNKs FOR TREATING CANCER

Номер: US20190002411A1
Автор: Mbatia Hannah, Njar Vincent, Ramalingam Senthilmurugan, Ramamurthy Vidya
Принадлежит: University of Maryland, Baltimore

The synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling are discussed. In both breast and prostate cancer cell lines, these compounds induce Mnk1/2 degradation to substantially suppress eIF4E phosphorylation. In prostate cancer cells, the compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to inhibit AR transcriptional activity. The consequences of these multiple activities resulted in inhibition of cell growth and migration and induction of apoptosis. Finally and importantly, the compounds demonstrate strong in vitro and in vivo anti-breast and anti-prostate cancer activities, with no apparent host toxicities. 2. The process as claimed in claim 1 , wherein the process is for the treatment of breast cancer or prostate cancer.3. The process as claimed in claim 2 , wherein R is an imidazole claim 2 , and wherein the compound is selected from the following:Compound 16 in which R′ is the hydrogen, and n is 0;Compound 17 in which R′ is a hydroxyl group in a para-position, and n is 0;Compound 18 in which R′ is a hydroxyl group in an ortho-position, and n is 0;Compound 19 in which R′ is a fluorine in a para-position, and n is 0;Compound 20 in which R′ is a fluorine in a meta-position, and n is 0;Compound 21 in which R′ is the hydrogen, and n is 1;Compound 22 in which R′ is the hydroxyl group in the para-position, and n is 1;Compound 23 in which R′ is the fluorine in the para-position, and n is 1;Compound 24 in which R′ is the fluorine in the meta-position, and n is 1; andCompound 25 in which R′ is the hydroxyl group in the para-position, and n is 2.4. The process as claimed in claim 3 , wherein the compound is selected from the following:Compound 16 in which R′ is the hydrogen, and n is 0;Compound 20 in which R′ is a fluorine in a meta-position, and n is 0; andCompound 22 in which R′ is the hydroxyl group in ...

Подробнее
Номер записи: 26
14-01-2016 дата публикации

Onium salt, liquid composition containing said onium salt and cellulose, and cellulose recovery method

Номер: US20160009669A1
Автор: Syuko SAKUGAWA, Yuko KOGA
Принадлежит: Koei Chemical Co Ltd

The invention relates to an onium salt, a liquid composition containing the onium salt and cellulose, and a method for recovering cellulose. The invention makes it possible to provide an onium salt having an extremely high ability to dissolve cellulose at temperatures of 100° C. or lower. It also makes it possible to provide a liquid composition containing this onium salt and cellulose, as a composition suitable for the recovery of cellulose, and a method for recovering cellulose efficiently by using such a liquid composition containing the onium salt and cellulose.

Подробнее
Номер записи: 27
14-01-2016 дата публикации

PHOTOBASE GENERATOR

Номер: US20160009737A1
Автор: Furuta Takeshi, Ikeda Takuya, SHIRAISHI Atsushi
Принадлежит: SAN-APRO LTD.

There is provided a photobase generator and a photosensitive resin composition containing the photobase generator. The photobase generator includes an ammonium salt represented by general formula (1). In formula (1), Rto Rindependently represent an alkyl group having 1 to 18 carbon atoms or Ar, wherein at least one of Rto Rrepresents Ar; Ar represents an aryl group having 6 to 14 carbon atoms (excluding carbon atoms contained in a substituent as mentioned below), wherein some of hydrogen atoms in the aryl group may be independently substituted by an alkyl group having 1 to 18 carbon atoms or the like; Y represents an ammonio group represented by general formula (2) or (3); and E represents a hydrogen atom or a group represented by general formula (5). 2. The photobase generator according to claim 1 , further comprising a photosensitizer as an active ingredient.3. The photobase generator according to claim 2 , wherein the photosensitizer is an aromatic ketone.4. The photobase generator according to claim 1 , wherein Ar of Rto Rin general formula (1) represents a phenyl group claim 1 , a naphthyl group claim 1 , a biphenylyl group or an anthryl group.5. The photobase generator according to claim 1 , wherein Y in general formula (1) represents an ammonio group represented by general formula (2).7. A photocurable composition claim 1 , comprising the photobase generator according to and a basic reactive compound.8. A cured product obtained by curing the photocurable composition according to . The present invention relates to a photobase generator generating a base by photoirradiation. More particularly, the present invention relates to a photobase generator suitably used for the production of a material to be cured by utilizing a base generated by photoirradiation (for example, a coating agent or a coating material) or a product or a member formed after being subjected to patterning in which the difference in solubility to a developing solution between the exposed part ...

Подробнее
Номер записи: 28
10-01-2019 дата публикации

METHOD FOR DECOLORING IONIC LIQUID

Номер: US20190009243A1
Автор: Kim Ki-hyun, OH Yong-Taeg, SHIN Dong-Chan
Принадлежит: Industry-Academic Cooperation Foundation Chosun University

A method of decoloring an ionic liquid includes preparing a discolored ionic liquid, and decoloring the discolored ionic liquid through irradiation with UV rays. An ionic liquid that is discolored due to heat treatment upon purification is decolored and can thus be reused. The method of decoloring the ionic liquid is effective because an ionic liquid, which is discolored due to heat treatment upon purification, can be decolored in a simple manner and also because an ionic liquid, which is discolored and is thus difficult to apply to the purification of an organic material, can be decolored in a simple manner, and can thus be reused in the form of a high-purity ionic liquid. 1. A method of decoloring an ionic liquid , comprising:preparing a discolored ionic liquid from an ionic liquid; anddecoloring the discolored ionic liquid through irradiation with UV rays.3. The method of claim 2 , wherein the ionic liquid includes at least one anion selected from the group consisting of Cl claim 2 , Br claim 2 , NO claim 2 , BF claim 2 , PF claim 2 , AlCl claim 2 , AlCl claim 2 , AcO claim 2 , CHCOO claim 2 , CFCOO claim 2 , CHSO claim 2 , CFSO claim 2 , (CFSO)N claim 2 , (CFSO)C claim 2 , (CFCFSO)N claim 2 , CFSO claim 2 , CF7COO claim 2 , (CFSO)(CFCO)N claim 2 , CFN claim 2 , CFNOS claim 2 , CFNOS claim 2 , CFNOS claim 2 , CFSO claim 2 , CFSO claim 2 , CFSO claim 2 , CFSO claim 2 , PF claim 2 , CHNOS claim 2 , CFNOS claim 2 , (CFSO)N claim 2 , and CHCH(OH)CO.4. The method of claim 1 , wherein the decoloring of the discolored ionic liquid is performed by irradiating the discolored ionic liquid with the UV rays in a UV range corresponding to an absorption wavelength of a cation contained in the ionic liquid before discoloration.5. The method of claim 2 , wherein the decoloring of the discolored ionic liquid is performed by irradiating the discolored ionic liquid with the UV rays in a UV range corresponding to an absorption wavelength of the cation contained in the ionic liquid ...

Подробнее
Номер записи: 29
08-01-2015 дата публикации

COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND A SUBSTITUTED IMIDAZOLE, METHODS AND USES THEREOF

Номер: US20150011601A1
Автор: Meng Charles Q.
Принадлежит: MERIAL LIMITED

This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof. 3. The composition of claim 2 , wherein:{'sub': '1b', 'Ris methyl, CN or halogen;'}{'sub': 2b', 'n', '14b, 'Ris S(O)R;'}{'sub': 14b', '1', '6', '1', '6, 'Ris C-C-alkyl or C-C-haloalkyl;'}{'sub': 3b', '7b', '8b, 'Ris —NRR,'}{'sub': 7b', '8b', '1', '6', '1', '6', '1', '6', 'r', '3', '1', '6', '1', '6, 'Rand Rindependently represent a hydrogen, C-C-alkyl, C-C-haloalkyl, —C(O)C-C-alkyl, —S(O)CF, C-C-acyl or C-C-alkoxycarbonyl radical;'}{'sub': 6b', '1', '6', '1', '6, 'Ris a halogen, C-C-haloalkyl, or C-C-haloalkoxy;'}m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and{'sub': '13b', 'Z is a C—Rradical.'}4. The composition of claim 2 , wherein:{'sub': '1b', 'Ris methyl, CN or halogen;'}{'sub': 2b', 'n', '14b, 'Ris S(O)R;'}{'sub': 14b', '1', '6', '1', '6, 'Ris C-C-alkyl or C-C-haloalkyl;'}{'sub': '3b', 'Ris alkyl or haloalkyl;'}{'sub': 6b', '1', '6', '1', '6, 'Ris a halogen, C-C-haloalkyl, or C-C-haloalkoxy;'}m, n, q and r represent, independently of one another, an integer equal to 0 or 1; and{'sub': '13b', 'Z is a C—Rradical.'}5. The composition of claim 1 , wherein the veterinarily acceptable carrier comprises acetone claim 1 , acetonitrile claim 1 , benzyl alcohol claim 1 , ethanol claim 1 , isopropanol claim 1 , diisobutyl adipate claim 1 , diisopropyl adipate claim 1 , butyl diglycol claim 1 , dipropylene glycol n-butyl ether claim 1 , ethylene glycol monoethyl ether claim 1 , ethylene glycol monomethyl ether claim 1 , dipropylene glycol monomethyl ether claim 1 , liquid polyoxyethylene glycols claim 1 , propylene glycol monomethyl ether claim 1 , ...

Подробнее
Номер записи: 30
17-01-2019 дата публикации

Selective androgen receptor degrader (sard) ligands and methods of use thereof

Номер: US20190015387A1
Автор: Dong-Jin Hwang, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy, Yali He
Принадлежит: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Подробнее
Номер записи: 31
18-01-2018 дата публикации

Ionic Liquid, Lubricant, and Magnetic Recording Medium

Номер: US20180016510A1
Автор: Hirofumi Kondo, Kouki Hatsuda, KyungSung Yun, Nobuo Tano
Принадлежит: Dexerials Corp

A lubricant, which includes an ionic liquid including a conjugate base and a conjugate acid including 2 or more cations in a molecule of the conjugate acid, wherein the conjugate acid includes a monovalent group including a straight-chain hydrocarbon group having 6 or more carbon atoms, and an acid that is a source of the conjugate base has a pKa in acetonitrile of 10 or less.

Подробнее
Номер записи: 32
21-01-2021 дата публикации

MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING

Номер: US20210015948A1
Автор: Caravan Peter, GALE Eric M.
Принадлежит:

Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets. 3. The compound of claim 1 , wherein Q is CH.4. The compound of claim 1 , wherein Y is CH.5. The compound of claim 1 , wherein at least one Y is CZ claim 1 , wherein Z is selected from the group consisting of COR claim 1 , C-Calkyl claim 1 , and OR.6. The compound of claim 1 , wherein one Y is CZ claim 1 , wherein Z is selected from the group consisting of COR claim 1 , C-Calkyl claim 1 , and OR claim 1 , and all other Y are CH.7. The compound of claim 1 , wherein each Ris H or C-Calkyl claim 1 , wherein the alkyl is optionally substituted by 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 OH groups.8. The compound of claim 1 , wherein Rand Rare each H.919.-. (canceled)20. The compound of claim 1 , wherein Ris C-Ccycloalkylene.23. The compound of claim 1 , wherein Ris a C-Calkylene.24. (canceled)26. The compound of claim 1 , wherein Ris H.27. The compound of claim 1 , wherein Ris H.2948.-. (canceled)52. The compound of claim 49 , wherein for each Dand D claim 49 , Ris 1 claim 49 ,2-cyclohexylene claim 49 , Ris H claim 49 , Ris H claim 49 , DG is Formula II claim 49 , Q is CH claim 49 , the Y positioned α- to Q is C-(L)-TBM or C-(L)-TBM claim 49 , and all other Y are CH claim 49 , and Land Lare each —C(O)—.54. A method of magnetic resonance (MR) imaging a patient claim 49 , the method comprising:{'claim-ref': {'@idref': 'CLM-00049', 'claim 49'}, 'a) administering to the patient an effective amount of a compound of ; and'}b) acquiring an MR image of the patient.5559.-. (canceled)61. The compound of claim 49 , wherein Q is CH.62. The compound of claim 49 , wherein Y is CH.63. The compound of claim 49 , wherein at least one Y is CZ claim 49 , wherein Z is selected from the group consisting of COR ...

Подробнее
Номер записи: 33
17-01-2019 дата публикации

ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS

Номер: US20190016684A1
Автор: Riduan Siti Nurhanna Binti, Yuan Yuan, Zhang Yugen
Принадлежит:

The present invention relates to antimicrobial imidazolium compounds having the structure of Formula (I) wherein R is an optionally substituted aliphatic group that is linear, cyclic, saturated, unsaturated or any combination thereof; n is an integer of at least 1; and X is an anionic counterion. The present invention also relates to pharmaceutical composition comprising the compound, a gel comprising the compound, uses of the compound as an antibiotic and methods for the preparation of the gels. 119-. (canceled)21. The gel according to claim 20 , wherein the gel is formed by self-assembly of the compound.22. The gel according to claim 20 , wherein the solvent is an alcohol.23. The gel according to claim 20 , wherein the gel comprises the compound having Formula (I) in the range of 4% to 15% by weight.24. The gel according to claim 20 , wherein R is an optionally substituted linear alkyl claim 20 , optionally substituted branched alkyl claim 20 , optionally substituted cyclic alkyl claim 20 , optionally substituted alkyl halide claim 20 , optionally substituted alkyl alkene claim 20 , optionally substituted alkyl alkyne or any combination thereof.25. The gel according to claim 24 , wherein R is selected from the group consisting of saturated liner alkyl or saturated cyclic alkyl comprising 5 to 20 carbon atoms.26. The gel according to claim 25 , wherein R is selected from the group consisting of saturated liner alkyl or saturated cyclic alkyl further comprising 6 to 16 carbon atoms.27. The gel according to claim 25 , wherein R is selected from the group consisting of cyclohexylmethyl (CHCH) claim 25 , hexyl (CH) claim 25 , octyl (CH) claim 25 , decyl (CH) claim 25 , dodecyl (CH) claim 25 , tetradecyl (CH) claim 25 , hexadecyl (CH) and any mixture thereof.28. The gel according to claim 20 , wherein n is 5 claim 20 , 6 or 7.29. The gel according to claim 20 , wherein X is halogen claim 20 , carbonate claim 20 , phosphate claim 20 , nitrate claim 20 , sulfate claim 20 ...

Подробнее
Номер записи: 34
17-01-2019 дата публикации

METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF

Номер: US20190016715A1
Автор: COSFORD Nicholas David Peter, Raveendra-Panickar DHANYA, SHEFFLER Douglas J.
Принадлежит:

Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions. 162.-. (canceled)65. The compound of claim 63 , or a pharmaceutically acceptable salt thereof claim 63 , wherein X is —O—.66. The compound of claim 63 , or a pharmaceutically acceptable salt thereof claim 63 , wherein Ris substituted or unsubstituted heteroaryl.67. The compound of claim 63 , or a pharmaceutically acceptable salt thereof claim 63 , wherein n is 1 and Ris halogen or —CH.68. The compound of claim 63 , or a pharmaceutically acceptable salt thereof claim 63 , wherein Ris —CF.69. The compound of claim 63 , or a pharmaceutically acceptable salt thereof claim 63 , wherein m is 0.71. A pharmaceutical composition comprising a compound of claim 63 , or a pharmaceutically acceptable salt claim 63 , and at least one pharmaceutically acceptable excipient.72. A method of treating a central nervous disorder (CNS) claim 63 , the method comprising the step of administering to a subject in need thereof claim 63 , an effective amount of a compound of claim 63 , thereby treating the disorder.75. The compound of claim 73 , or a pharmaceutically acceptable salt thereof claim 73 , wherein X is —O—.76. The compound of claim 73 , or a pharmaceutically acceptable salt thereof claim 73 , wherein Ris substituted or unsubstituted heteroaryl.77. The compound of claim 73 , or a pharmaceutically acceptable salt thereof claim 73 , wherein n is 1 and Ris halogen or —CH.78. The compound of claim 73 , or a pharmaceutically acceptable salt thereof claim 73 , wherein Ris —CF.79. The compound of claim 73 , or a pharmaceutically acceptable salt thereof claim 73 , wherein m is 0.81. A pharmaceutical composition comprising a compound of claim 73 , or a pharmaceutically acceptable salt claim 73 , and at least one pharmaceutically acceptable excipient.82. A method of treating ...

Подробнее
Номер записи: 35
18-01-2018 дата публикации

ELECTROCHEMICAL METHODS, DEVICES AND COMPOSITIONS

Номер: US20180019496A1
Автор: KONOPKA Daniel A., Seedig Jason A.
Принадлежит: Alligant Scientific, LLC

The disclosure provides a method comprising inducing a first current between a source of a countercharge and a first electrode, the first current being through an electrolyte. A second current is induced across the first electrode, the second current being transverse to the first current, and the second current inducing a relativistic charge across the first electrode. 1. An apparatus , comprising:a source of countercharge;an electrode;an electrolyte in contact with the electrode and through which a first current between the source of countercharge and electrode flows; anda waveform generating device coupled with the electrode, the waveform generating device inducing an electric waveform across the electrode in the presence of the current.2. The apparatus of claim 1 , wherein electric waveform is a second current.3. The apparatus of claim 1 , wherein the electric waveform is a potential across the electrode.4. The apparatus of claim 1 , wherein the electric waveform is selected from the group consisting of sinusoid claim 1 , square claim 1 , triangle claim 1 , ramp claim 1 , saw tooth claim 1 , and combinations thereof.5. The apparatus of claim 1 , wherein the electric waveform comprises a plurality of waveforms based on harmonics of one or more frequencies at which the electrolyte or the electrode exhibits absorption of the one or more frequencies.6. The apparatus of claim 1 , wherein the electric waveform has a period matched to a diffusion rate of a component in the electrolyte.7. The apparatus of claim 1 , wherein the electric waveform in the presence of the first current bends electric field lines proximate the electrode to effect deposition of metal from the electrolyte onto the electrode and corrosion of metal from the electrode into the electrolyte.8. The apparatus of claim 1 , wherein the electric waveform relativistically charges the electrode to effect deposition of metal from the electrolyte onto the electrode and corrosion of metal from the electrode ...

Подробнее
Номер записи: 36
25-01-2018 дата публикации

PRODUCTION METHOD FOR INCLUSION COMPOUND

Номер: US20180022675A1
Автор: HOSHI Eiji, Ono Kazuo
Принадлежит: NIPPON SODA CO., LTD.

A method for producing a thermodynamically more stable clathrate compound including at least one compound selected from the group consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane, 5-hydroxyisophthalic acid, and 5-nitroisophthalic acid as a host compound and an imidazole compound as a guest compound. The method for producing a clathrate compound includes: a mixing step of mixing a mixed solvent including a protic solvent, at least one compound selected from the group consisting of 1,1,2,2-tetrakis(4-hydroxyphenyl)ethane, 5-hydroxyisophthalic acid and 5-nitroisophthalic acid, and an imidazole compound; and a heating step. 3. The method for producing a clathrate compound according to claim 1 , wherein the mixed solvent comprises a first solvent which is at least one solvent selected from the group consisting of water and methanol and a second solvent which is at least one solvent selected from the group consisting of an alcoholic solvent claim 1 , an ester-based solvent claim 1 , a ketone-based solvent claim 1 , an aliphatic hydrocarbon-based solvent claim 1 , and an aromatic hydrocarbon-based solvent claim 1 , the second solvent being a solvent different from the first solvent.4. The method for producing a clathrate compound according to claim 1 , wherein the imidazole compound represented by formula (I) is 2-phenyl-4-methyl-5-hydroxymethylimidazole or 2-ethyl-4-methylimidazole.5. The method for producing a clathrate compound according to claim 2 , wherein the mixed solvent comprises a first solvent which is at least one solvent selected from the group consisting of water and methanol and a second solvent which is at least one solvent selected from the group consisting of an alcoholic solvent claim 2 , an ester-based solvent claim 2 , a ketone-based solvent claim 2 , an aliphatic hydrocarbon-based solvent claim 2 , and an aromatic hydrocarbon-based solvent claim 2 , the second solvent being a solvent different from the first solvent.6. The method for producing a ...

Подробнее
Номер записи: 37
04-02-2016 дата публикации

Arginine methyltransferase inhibitors and uses thereof

Номер: US20160031839A1
Автор: Gideon Shapiro, Lorna Helen Mitchell, Richard Chesworth
Принадлежит: Epizyme Inc

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Подробнее
Номер записи: 38
17-02-2022 дата публикации

METHOD FOR PRODUCING AMIDATE COMPOUND, AND AMIDATE COMPOUND

Номер: US20220048864A1
Автор: MIYAGI Motoyoshi, NITTA Shingo, ONODA Mitsuki
Принадлежит: KOEI CHEMICAL COMPANY, LIMITED

A method for producing an amidate compound represented by Formula (4), comprising reacting an iminium salt represented by Formula (1) and an organic compound represented by Formula (3), wherein Formulas (1), (3), and (4) are as defined in the description. 4. The method for producing an amidate compound according to claim 1 , wherein Q is an —NHCORgroup.6. The method for producing an amidate compound according to claim 1 , wherein A is an unsubstituted hydrocarbon group or a hydrocarbon group having at least one substituent selected from a halogen atom claim 1 , an alkylamino group claim 1 , a dialkylamino group claim 1 , an alkoxy group claim 1 , an aryloxy group claim 1 , a nitro group claim 1 , a cyano group claim 1 , a sulfonyl group claim 1 , an (alkylamino)carbonylamino group claim 1 , a (dialkylamino)carbonylamino group claim 1 , and an isocyanate group.7. The method for producing an amidate compound according to claim 1 , wherein n is an integer of 1 to 6.9. The amidate compound according to claim 8 , wherein A is an unsubstituted hydrocarbon group or a hydrocarbon group having at least one substituent selected from a halogen atom claim 8 , an alkylamino group claim 8 , a dialkylamino group claim 8 , an alkoxy group claim 8 , an aryloxy group claim 8 , a nitro group claim 8 , a cyano group claim 8 , a sulfonyl group claim 8 , an (alkylamino)carbonylamino group claim 8 , a (dialkylamino)carbonylamino group claim 8 , and an isocyanate group.10. The amidate compound according to claim 8 , wherein n is an integer of 1 to 6.14. A thermosetting composition comprising the blocking agent dissociation catalyst for blocked isocyanates according to claim 13 , a blocked isocyanate claim 13 , and a compound having an isocyanate-reactive group. The present invention relates to a method for producing an amidate compound, and an amidate compound.Known conventional methods for producing amidate compounds include (1) a method comprising reacting alkylimidazole with dimethyl ...

Подробнее
Номер записи: 39
04-02-2021 дата публикации

Insecticidal compositions and methods

Номер: US20210030001A1
Автор: Christina Marie TAYLOR, Matthew Dimmic, Michael J. Crawford, Rae LAWRENCE
Принадлежит: MONSANTO TECHNOLOGY LLC

Substituted imidazole and substituted pyrazole compounds and compositions derived therefrom can be useful in controlling insect pests. Suitable imidazole compounds can be analogues of 2,4,5-triphenyl-1H-imidazole, wherein the C-2 phenyl group bears at least one substitution, the C-4 and C-5 phenyl groups are optionally substituted, and N-1 is unsubstituted. Suitable pyrazole compounds can bear a 1,3,4-substitution pattern, with an optionally substituted aryl or optionally substituted alkyl group being present at N-1, an optionally substituted aryl or optionally substituted heteroaryl group being present at C-3, and a secondary amide group being present at C-4. These compounds and compositions derived therefrom can be administered to a plant, seed, soil or insect to control a variety of insect pests.

Подробнее
Номер записи: 40
04-02-2021 дата публикации

USE OF PYDIFLUMETOFEN FOR THE REDUCTION OF MYCOTOXIN CONTAMINATION IN PLANTS

Номер: US20210030002A1
Автор: Coqueron Pierre-Yves, Dahmen Peter, Wetcholowsky Ingo
Принадлежит:

The present invention relates to the novel use of the pyrazole carboxylic acid amide derivative Pydiflumetofen, compositions comprising this compound and its use in methods for the reduction of mycotoxin contamination in plants. Pydiflumetofen is also useful in increasing yield, in particular in cereals eg. wheat. 2. The method according to wherein the compound of Formula I and prothioconazole are applied in a liquid composition.4. The method according to wherein the compound of formula (I) and the prothioconazole are applied in a liquid composition.5. A plant which has been treated by the method according to .6. The method according to claim 1 , wherein the plant is wheat.7. The method according to claim 1 , wherein the plant has at least 80% less deoxynivalenol contamination than a plant which has not been treated.8. The method of claim 1 , wherein the compound of formula (I) and the prothioconazole are applied during flowering. This application is a Continuation of U.S. patent application Ser. No. 15/766,726, filed 6 Apr. 2018, which is a National Stage entry of International Application No. PCT/EP2016/074109, filed 7 Oct. 2016, which claims priority to European Patent Application No 15189239.5, filed 9 Oct. 2015. Each of these applications is incorporated by reference in its entiretyThe present invention relates to the novel use of the pyrazole carboxylic acid amide derivative Pydiflumetofen, compositions comprising this compound and its use in methods for the reduction of mycotoxin contamination in plants. Pydiflumetofen is also useful in increasing yield, in particular in cereals eg. wheat.Numerous fungi are serious pests of economically important agricultural crops. Further, crop contamination by fungal toxins is a major problem for agriculture throughout the world.Mycotoxins, such as aflatoxins, ochratoxins, patulin, fumonisins, zearalenones, and trichothecenes, are toxic fungal metabolites, often found in agricultural products that are characterized by ...

Подробнее
Номер записи: 41
31-01-2019 дата публикации

IONIC LIQUIDS COMPRISING HETERAROMATIC ANIONS

Номер: US20190031608A1
Автор: Brennecke Joan F., Goodrich Brett, Gurkan Burcu, Maginn Edward J., Mindrup Elaine, Price Erica, Schneider William F.
Принадлежит:

Some embodiments described herein relate to ionic liquids comprising an anion of a heteraromatic compound such as optionally substituted pyrrolide, optionally substituted pyrazolide, optionally substituted indolide, optionally substituted phospholide, or optionally substituted imidazolide. Methods and devices for gas separation or gas absorption related to these ionic liquids are also described herein. 2. The ionic liquid of claim 1 , wherein Rand Rare H and Ris NO.4. The method of claim 3 , wherein the mixture of gases is an exhaust from combustion of a carbon-based fuel claim 3 , wherein the carbon-based fuel is coal claim 3 , a petroleum product claim 3 , or natural gas.5. The method of claim 3 , wherein the mixture of gases further comprises an oxide of sulfur or nitrogen.6. The method of claim 3 , further comprising recovering the carbon dioxide from the second ionic liquid by applying at least one of heat or reduced pressure to the second ionic liquid.8. The gas separation system of claim 3 , further comprising a regeneration component wherein the ionic liquid according to is subjected to heat and/or reduced pressure to liberate carbon dioxide.9. A combustion device comprising:a combustion vessel configured to contain a combustion reaction;an exhaust component, in fluid communication with the combustion vessel, which is configured to allow exhaust from the combustion reaction to escape from the combustion vessel, wherein the exhaust comprises carbon dioxide; and{'claim-ref': {'@idref': 'CLM-00007', 'claim 7'}, 'the gas separation system of , coupled to the exhaust component;'}wherein the device is configured to provide sufficient contact between the exhaust and the separation system to remove at least a portion of the carbon dioxide from the exhaust. This application is a continuation of U.S. patent application Ser. No. 15/802,360, filed on Nov. 2, 2017, which is a divisional of U.S. patent application Ser. No. 13/505,730, filed on May 2, 2012, now U.S. Pat. ...

Подробнее
Номер записи: 42
30-01-2020 дата публикации

METHOD OF DETERMINING AN AMOUNT OF WATER IN A SAMPLE USING A DERIVATIVE OF IMIDAZOLE AND A HYDROGEN HALIDE DONOR

Номер: US20200033307A1
Автор: Neufeld Roman
Принадлежит: HONEYWELL INTERNATIONAL INC.

A method for determining an amount of water in a sample includes utilizing a reagent and includes sulfur dioxide or derivative thereof, a protic or aprotic solvent or combinations thereof, a derivative of imidazole that has the following structure: 3. The method of wherein:the sulfur dioxide or derivative thereof is present in an amount of from about 0.01 to about 5, mols/liter of the reagent,the derivative of imidazole is present in an amount of from about 0.1 to about 10, mols/liter of the reagent,the hydrohalide of the second derivative of imidazole is present in an amount of from about 0.01 to about 3, mols/liter of the reagent,wherein the reagent optionally comprises a hydrohalide acceptor present in an amount of from 0 to about 10 mols/liter of the reagent, andwherein the solvent comprises a balance of the reagent.4. The method of wherein:the sulfur dioxide or derivative thereof is present in an amount of from about 0.2 to about 0.9, mols/liter of the reagent,the derivative of imidazole is present in an amount of from about 1 to about 1.8, mols/liter of the reagent,the hydrohalide of the second derivative of imidazole is present in an amount of from about 0.15 to about 0.9, mols/liter of the reagent,wherein the reagent optionally comprises a hydrohalide acceptor present in an amount of from 0 to about 2 mols/liter of the reagent, andwherein the solvent comprises a balance of the reagent.7. The method of wherein the solvent is an aprotic solvent and is chosen from propylene carbonate claim 1 , acetonitrile claim 1 , N claim 1 ,N-dimethylformamide claim 1 , N-methylformamide claim 1 , acetamide formamide claim 1 , N-methyl acetamide claim 1 , N-dimethyl acetamide claim 1 , 2-pyrrolidone claim 1 , N-methyl-2-pyrrolidone claim 1 , chloroform claim 1 , dichloromethane claim 1 , bromoform claim 1 , dibromomethane claim 1 , and/or the said solvent is an protic solvent and comprises a balance of the reagent and chosen from methanol claim 1 , ethanol claim 1 , propanol ...

Подробнее
Номер записи: 43
05-02-2015 дата публикации

Benzamides and nicotinamides as syk modulators

Номер: US20150038492A1
Автор: Anjali Pandey, Brian Kane, Qing Xu, Shawn M. Bauer, Yonghong Song, Zhaozhong J. Jia
Принадлежит: Portola Pharmaceuticals LLC

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Подробнее
Номер записи: 44
08-02-2018 дата публикации

BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA

Номер: US20180036296A1
Автор: GOLDMAN Erick A., HUANG Wenrong, Li Wenhao, Scarborough Robert M., Song Yonghong, Wang Lingyan, Zhang Penglie, Zhu Bing-Yan, ZUCKETT Jingmei
Принадлежит:

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders. 172.-. (canceled)74. The method of claim 73 , wherein the salt is the maleate salt.75. The method of claim 73 , wherein the compound is administered to the mammal in the form of a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.76. The method of claim 75 , wherein the pharmaceutical composition is in capsule form.78. The method of claim 77 , wherein the salt is the maleate salt.79. The method of claim 77 , wherein the compound is administered to the mammal in the form of a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.80. The method of claim 79 , wherein the pharmaceutical composition is in capsule form.82. The method of claim 81 , wherein the salt is the maleate salt.83. The method of claim 81 , wherein the compound is administered to the mammal in the form of a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.84. The method of claim 83 , wherein the pharmaceutical composition is in capsule form. This invention relates to novel compounds which are potent and highly selective inhibitors of isolated factor Xa or when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, fIXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin). In another aspect, the present invention relates to novel monoamidino-containing compounds, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof which are useful as potent and specific inhibitors of blood ...

Подробнее
Номер записи: 45
08-02-2018 дата публикации

SUBSTITUTED QUINOLINES AS PDE-10 INHIBITORS

Номер: US20180037590A1
Автор: CAMPBELL John Emmerson, HEWITT Michael Charles, Jones Philip Xinhe, Xie Linghong
Принадлежит:

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes. 2. The compound of claim 1 , wherein L is —CH—CH— claim 1 , —CH═CH— claim 1 , —O—CH— claim 1 , —NH—CH— claim 1 , —CH—O— claim 1 , —CH—NH— claim 1 , —CHS— claim 1 , or —S—.3. The compound of claim 2 , wherein L is —CH—CH—.5. The compound of claim 4 , wherein Ais NR; and Ris (i) hydrogen; or (ii) (C-C)alkyl claim 4 , (C-C)alkenyl claim 4 , (C-C)heteroalkyl claim 4 , (C-C)cycloalkyl claim 4 , (6 to 10 membered) aryl claim 4 , (5 to 10 membered) heteroaryl claim 4 , (3 to 12 membered)heterocyclyl claim 4 , carbonyl claim 4 , or sulfonyl claim 4 , each of which is optionally substituted with one or more R; or (iii) Rand Rtogether with the atoms to which they are attached form a ring optionally substituted with one or more R.6. The compound of claim 5 , wherein Ris H or CH.8. The compound of claim 7 , wherein Ris (i) hydrogen; or (ii) alkyl claim 7 , aryl claim 7 , or heteroaryl claim 7 , each of which is optionally substituted with one or more R.9. The compound of or claim 7 , wherein Ris (i) hydrogen; or (ii) alkyl claim 7 , aryl claim 7 , or heteroaryl claim 7 , each of which is optionally substituted with one or more R.10. The compound of any one of to claim 7 , wherein Ris (i) hydrogen; or (ii) alkyl claim 7 , aryl claim 7 , or heteroaryl claim 7 , each of which is optionally substituted with one or more R.11. The compound of any one of to claim 7 , wherein each occurrence of Ris independently (i) hydrogen; or (ii) alky claim 7 , aryl or heteroaryl claim 7 , each of which is optionally substituted with one or more R.14. The compound of ...

Подробнее
Номер записи: 46
09-02-2017 дата публикации

Method of electroplating photoresist defined features from copper electroplating baths containing reaction products of imidazole compounds, bisepoxides and halobenzyl compounds

Номер: US20170037528A1
Автор: Erik Reddington, Julia KOZHUKH, Julia WOERTINK, Mark Lefebvre, Matthew Thorseth, Yi Qin, Zuhra Niazimbetova
Принадлежит: Dow Global Technologies LLC, Rohm and Haas Electronic Materials LLC

Electroplating methods enable the plating of photoresist defined features which have substantially uniform morphology. The electroplating methods include copper electroplating baths with reaction products of imidazole compounds, bisepoxides and halobenzyl compounds to electroplate the photoresist defined features. Such features include pillars, bond pads and line space features.

Подробнее
Номер записи: 47
12-02-2015 дата публикации

IONIC LIQUID AS LUBRICATING OIL BASE STOCKS, COBASE STOCKS AND MULTIFUNCTIONAL FUNCTIONAL FLUIDS

Номер: US20150045266A1
Автор: Bodige Satish, Guney Tezcan, Patil Abhimanyu Onkar
Принадлежит: EXXONMOBIL RESEARCH AND ENGINEERING COMPANY

A composition including an ionic liquid alkyl ammonium salt (e.g., tetraalkylammonium cation and bis(trifluoromethanesulfonyl)imide anion) or an ionic liquid imidazolium salt (e.g., 1,3-dialkylimidazolium cation and bis(trifluoromethanesulfonyl)imide anion), that have a structure sufficient to exhibit at least partial solubility in one or more Group I-V base stocks. The disclosure also relates to a lubricating oil base stock and lubricating oil containing the composition, a multifunctional functional fluid containing the composition, and a method for improving solubility of an ionic liquid in a lubricating oil by using as the lubricating oil a formulated oil including a lubricating oil base stock as a major component, and an ionic liquid alkylammonium salt cobase stock, or an ionic liquid imidazolium salt cobase stock, as a minor component. 3. The composition of wherein claim 1 , in formula (1) claim 1 , R is independently CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CHor CH; and wherein claim 1 , in formula (2) claim 1 , Ris CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , or CH claim 1 , and Ris CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , CH claim 1 , or CH.4. The composition of wherein said ionic liquid alkylammonium salt of formula (1) has a solubility in one or more Group I-V base stocks of at least 5% claim 1 , and said ionic liquid imidazolium salt of formula (2) has a solubility in one or more Group I-V base stocks of at least 5%.5. The composition of wherein said one or more Group I-V base stocks comprises a Group V base stock.6. The composition of which has an onset of thermal decomposition temperature greater than 250° C.7. The composition of having a viscosity (Kv) from 2 to 400 at 100° C. claim 1 , and a viscosity index (VI) from 100 to 300.10. The lubricating oil of wherein the lubricating oil base stock comprises a Group I claim 9 , II claim 9 ...

Подробнее
Номер записи: 48
18-02-2016 дата публикации

Methods of producing sulfilimine compounds

Номер: US20160046580A1
Автор: Timothy J. Adaway
Принадлежит: DOW AGROSCIENCES LLC

Methods of producing a sulfilimine compound, such as N-cyano-S-methyl-S-[1-(6-trifluoromethyl-3-pyridinyl)ethyl]sulfilimine or other substituted sulfilimine compound. The method includes combining a sulfide compound, cyanamide, a hypochlorite compound, and a base, and oxidizing the sulfide compound to form the sulfilimine compound. The sulfide compound may include a 2-trifluoromethyl-5-(1-substituted)alkyl-thiopyridine compound. The base may include sodium hydroxide. A buffer, such as a phosphate buffer, may, optionally, be used in the reaction.

Подробнее
Номер записи: 49
15-02-2018 дата публикации

METHOD FOR THE PREPARATION OF METAL-ORGANIC COMPOUNDS

Номер: US20180043330A1
Автор: FRISCIC Tomislav, GIRARD Simon, LI Chao-Jun, MOTTILLO Cristina, NICKELS Christopher Walter
Принадлежит:

A method for the preparation of a metal-organic compound is provided. This method comprises the steps of (a) providing at least one metal precursor, (b) providing at least one bridging organic ligand, and (c) exposing together the metal precursor and the ligand to liquid COor supercritical COas a reaction medium, thereby producing said metal-organic compound. 1. A method for the manufacture of a metal-organic compound , the method comprising the steps of:(a) providing at least one metal precursor,(b) providing at least one bridging organic ligand, and{'sub': 2', '2, '(c) exposing together the metal precursor and the ligand to liquid COor supercritical COas a reaction medium, thereby producing said metal-organic compound.'}2. The method of claim 1 , wherein during step (c) claim 1 , the metal precursor and the ligand are stirred with the liquid COor supercritical CO.3. The method of or claim 1 , wherein during step (c) claim 1 , the metal precursor and the ligand are together exposed to supercritical CO.4. The method of or claim 1 , wherein during step (c) claim 1 , the metal precursor and the ligand are together exposed to liquid CO.5. The method of any one of to claim 1 , wherein step c) is carried out at a temperature ranging between about 0° C. and about 100° C.6. The method of claim 5 , wherein step c) is carried out at a temperature ranging between about 20° C. and about 90° C.7. The method of claim 6 , wherein step c) is carried out at a temperature ranging between about 40° C. and about 80° C.8. The method of claim 7 , wherein step c) is carried out at a temperature ranging between about 50° C. and about 70° C.9. The method of claim 8 , wherein step c) is carried out at a temperature of about 60° C.10. The method of any one of to claim 8 , wherein step c) is carried out at a pressure ranging between about 80 bar and about 140 bar.11. The method of claim 10 , wherein step c) is carried out at a pressure ranging between about 90 bar and about 140 bar.12. The ...

Подробнее
Номер записи: 50
01-05-2014 дата публикации

HIGH MOLECULAR WEIGHT POLYLACTIC ACID SYNTHESIZED VIA POLYCONDENSATION CATALYZED BY BIONIC CREATININE GUANIDININIUM CHLORIDE

Номер: US20140121347A1
Автор: Huang Wei, Jiang Wei, LI HONG, Pan Bingcai, Zhang Quanxing, Zong Xupeng
Принадлежит: NANJING UNIVERSITY

Disclosed is a high molecular weight polylactic acid synthesized by using a method for synthesizing and catalytically-polycondensing bionic creatinine-guanidinium chloride. Creatinine is used as the material in a reaction with aqueous hydrochloric acid to synthesize a bionic creatinine-guanidinium salt catalyst, creatinine-guanidinium chloride (CR.Cl). The creatinine-guanidinium chloride synthesized is used as a catalyst, an industrial grade lactic acid (LA, 85% to 90%, aqueous solution) is used as a monomer, a solvent-free two-step polycondensation method is used to synthesize and afford metal-free and toxic residue-free polylactic acid featuring high biological safety and high molecular weight. 13-. (canceled)6. The method according to claim 5 , wherein the high molecular weight polylactic acid has a weight average molecular weight (Mw) of from about 1.4×10to about 2.5×10. The present invention belongs to the field of biodegradable medical materials, relating to a process for synthesizing polylactic acid featuring a high biological safety and a high molecular weight via polycondensation, wherein a bionic organic guanidinium salt, creatinine-guanidinium chloride, is used as catalyst.In recent years, along with the rapid development of medicine, pharmacy and biological tissue engineering, the demand for materials featuring good biocompatibility, biological safety and biodegradability is rapidly growing throughout the world. Biodegradable polylactic acid has been extensively applied in modern pharmaceutical science (controlled-released and targeted drug carriers), biological tissue engineering science (surgical sutures, bone screws, fracture splints, meniscus-repairing materials and devices, cells and bioactive species scaffold materials) and the like. It is required that the polymers used in the field of pharmacy and medicine should not contain any metal and toxic ingredient. Currently, the production of commercially available polylactic acid is mainly performed as ...

Подробнее
Номер записи: 51
16-02-2017 дата публикации

RUTHENIUM-BASED TRIAZOLE CARBENE COMPLEXES

Номер: US20170044195A1
Автор: BAGH BIDRAHA, MCKINTY ADAM, STEPHAN DOUGLAS WADE
Принадлежит: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO

The present invention relates to novel ruthenium-based triazole carbene complexes comprising specific ligands, their preparation and their use as catalysts in hydrogenation processes. Such complex catalysts are inexpensive, thermally robust, gel formation inhibiting and olefin selective. 2. The catalyst according to claim 1 , wherein:{'sub': 6', '10', '6', '10', '2', '3', '3, 'sup': 3', '3', '3, 'R is independently of one another hydrogen, halogen, nitro, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl or tert-butyl, phenyl, or together with the carbon atoms to which they are bound form a C-C-cycloalkyl or C-C-aryl substituent, alkyl thiolate, aryl thiolate, B(R)or B(R), whereas Ris alkyl, aryl, alkoxy or aryloxy or CF,'}n is 0 to 4, preferably 0 to 2, more preferably 0 to 1{'sup': 1', '2, 'sub': '1', 'Rand Rare identical or different and are each methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl or neopentyl, cyclohexyl, adamantyl, phenyl, C-methanesulphonate, p-toluenesulphonate, 2,4,6-trimethylphenyl (Mes) or 2,4,6-triisopropylphenyl (Trip),'}{'sub': 1', '30', '6', '24, 'X is hydride, halide pseudohalide, alkoxide, amide, triflate, phosphate, borate, straight-chain or branched C-C-alkyl or C-C-aryl, carboxylate, acetate, halogenated acetate, halogenated alkylsulfonate, tosylate or any weakly coordinating anionic ligands, and'}{'sup': 1', '2, 'sub': 1', '10', '3', '20', '3', '1', '10', '1', '10', '1', '10', '1', '10', '1', '10', '1', '10', '1', '10', '1', '10', '1', '10', '1', '5', '1', '5, 'Yand Yare identical or different and are each C-C-alkylphosphine or C-C-cycloalkylphosphine ligand, preferably tricyclohexylphosphine (PCy), a sulfonated C-C-alkylphosphine ligand, a C-C-alkylphosphinite ligand, a C-C-alkylphosphonite ligand, a C-C-alkyl phosphite ligand, a C-C-alkylarsine ligand, a C-C-alkylamine ligand, a substituted or not substituted pyridine ligand, a C-C-alkyl sulfoxide ligand, a C-C-alkyloxy ligand or a C-C ...

Подробнее
Номер записи: 52
07-02-2019 дата публикации

ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES

Номер: US20190044075A1
Автор: LIN Chun, Tsai Jui-Yi, Xia Chuanjun
Принадлежит: UNIVERSAL DISPLAY CORPORATION

A novel method for forming a metal-carbene bond is disclosed. 1. A method for forming a metal-carbene bond , the method comprising:mixing a metal precursor with a carbene salt, a weak base salt, and a solvent to form a reaction mixture; andheating the reaction mixture, wherein the weak base salt has pKa greater than 4, whereby the reaction mixture comprises a metal-carbene complex.2. The method of claim 1 , wherein the metal precursor is a second or third row transition metal.3. The method of claim 1 , wherein the metal precursor is selected from the group consisting of Ir claim 1 , Rh claim 1 , Re claim 1 , Ru claim 1 , Os claim 1 , Pt claim 1 , and Pd.4. The method of claim 1 , wherein the metal precursor is a halide salt.5. The method of claim 1 , wherein the metal precursor is selected from the group consisting of KPtCl claim 1 , NaPtCl claim 1 , PtCl claim 1 , PtCl(DMSO) claim 1 , Pt(COD)Cl claim 1 , IrCl.xHO claim 1 , NaIrCl.xHO claim 1 , (NH)IrCl claim 1 , KIrCl.xHO claim 1 , NaIrBr claim 1 , [(COD)IrCl] claim 1 , OsCl.xHO claim 1 , (NH)OsCl claim 1 , NaOsCl claim 1 , and OsCl(DMSO).6. The method of claim 1 , wherein the carbene salt is a carbon carbene salt.7. The method of claim 1 , wherein the carbene salt is a N-heterocyclic carbene salt.8. The method of claim 1 , wherein the carbene salt comprises a tetradentate ligand.9. The method of claim 1 , wherein the carbene salt is a carbene halide salt.10. The method of claim 1 , wherein the weak base salt is selected from the group consisting of: sodium acetate claim 1 , potassium acetate claim 1 , sodium butyrate claim 1 , potassium butyrate claim 1 , sodium propionate claim 1 , and potassium propionate.11. The method of claim 1 , wherein the solvent is the corresponding weak acid of the weak base salt.12. The method of claim 1 , wherein the solvent is selected from the group consisting of acetic acid claim 1 , propanoic acid claim 1 , pivalic acid claim 1 , and butyric acid.13. The method of claim 1 , wherein ...

Подробнее
Номер записи: 53
15-02-2018 дата публикации

COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME

Номер: US20180047907A1
Автор: Chen Chi-Chung, LIAO Liang-Di, LU Tai-Ni, SHIEH Shwu-Ju
Принадлежит: NICHEM FINE TECHNOLOGY CO., LTD.

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): 2. The compound as claimed in claim 1 , wherein the polycyclic aromatic ring extended from Xand Xis selected from the group consisting of: a substituted or unsubstituted naphthalene ring claim 1 , a substituted or unsubstituted anthracene ring claim 1 , a substituted or unsubstituted phenanthrene ring claim 1 , a substituted or unsubstituted fluorene ring claim 1 , a substituted or unsubstituted pyrene ring claim 1 , a substituted or unsubstituted benzophenanthrene ring claim 1 , a substituted or unsubstituted benzopyrene ring claim 1 , a substituted or unsubstituted fluoranthene ring claim 1 , and a substituted or unsubstituted benzofluoranthene ring.4. The compound as claimed in claim 1 , wherein the aryl ring extended from Xand Xis a substituted or unsubstituted 6 to 60-membered carbon ring.5. The compound as claimed in claim 4 , wherein the substituted or unsubstituted 6 to 60-membered carbon ring is selected from the group consisting of: a substituted or unsubstituted benzene ring claim 4 , a substituted or unsubstituted naphthalene ring claim 4 , a substituted or unsubstituted anthracene ring claim 4 , a substituted or unsubstituted phenanthrene ring claim 4 , a substituted or unsubstituted flourene ring claim 4 , a substituted or unsubstituted pyrene ring claim 4 , a substituted or unsubstituted benzophenanthrene ring claim 4 , a substituted or unsubstituted benzopyrene ring claim 4 , a substituted or unsubstituted fluoranthene ring claim 4 , and a substituted or unsubstituted benzofluoranthene ring.6. The compound as claimed in claim 4 , wherein the substituted or unsubstituted 6 to 60-membered carbon ring is a substituted or unsubstituted benzene ring.7. The compound as claimed in claim 1 , wherein at least one of Zto Zin formula (I) is selected from the group consisting of: an alkyl group having 1 to 40 carbon atoms ...

Подробнее
Номер записи: 54
14-02-2019 дата публикации

IMIDAZOLES AND IMIDAZOLIUM CATIONS WITH EXCEPTIONAL ALKALINE STABILITY

Номер: US20190047963A1
Автор: Coates Geoffrey W., Hugar Kristina M.
Принадлежит: CORNELL UNIVERSITY

The invention provides: imidazole and imidazolium compounds of formulas (I) and (II): 2. A compound according to of formula (I) claim 1 , wherein Ris selected from C-Chydrocarbyl claim 1 , or of formula (II) claim 1 , wherein Rand Rare independently selected from C-Chydrocarbyl.3. (canceled)4. (canceled)6. A compound according to claim 5 , wherein at least two of R claim 5 , R claim 5 , and Rare individually selected from methyl and isopropyl.7. A compound according to claim 1 , wherein Rand Rare individually selected from phenyl and C-Calkyl.8. A compound according to :{'sup': 3', '6a', '6c', '6b', '4', '5, 'of formula (I), wherein: Ris n-butyl; Rand Rare methyl, and Ris hydrogen; and Rand Rare individually selected from phenyl and methyl; or'}{'sup': 1', '3', '6a', '6c', '6b', '4', '5, 'of formula (II), wherein: Rand Rare each n-butyl; Rand Rare methyl, and Ris hydrogen; and Rand Rare individually selected from phenyl and methyl.'}9. A compound according to claim 1 , wherein Xis selected from hydroxide claim 1 , halide claim 1 , bicarbonate claim 1 , carbonate claim 1 , nitrate claim 1 , cyanide claim 1 , carboxylate and alkoxide.10. A compound according to claim 1 , the compound having an alkaline stability of greater than or equal to 95% cation remaining after 30 days in 5M KOH/CDOH at 80° C.12. (canceled)13. (canceled)16. A polymer according to claim 14 , wherein Ris selected from C-Chydrocarbyl.1723-. (canceled)2629-. (canceled)30. A polymer according to claim 24 , wherein Zis —(CH)—(Ph)—(CH)— claim 24 , wherein: p is 1-6; q is 0 or 1; and r is 1-6.31. (canceled)36. (canceled)37. (canceled)38. A membrane or device comprising a polymer according to .39. (canceled)40. (canceled) This application claims priority to U.S. Provisional Application No. 62/147,388, filed on Apr. 14, 2015, the entire contents of which are hereby incorporated herein by reference.This invention was made with Government support under Grant Number DE-SC0001086 awarded by US Department of ...

Подробнее
Номер записи: 55
23-02-2017 дата публикации

INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF

Номер: US20170050924A1
Автор: MARTINEZ Eduardo J., TAVAZONE Sohail F.
Принадлежит:

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer. 2. The compound of claim 1 , wherein Ris hydrogen.4. The compound of any one of to claim 1 , wherein Rcombines with Rwith the atoms to which they are attached to form an optionally substituted C-Ccycloalkyl ring.7. The compound of any one of to claim 1 , wherein Ris hydrogen claim 1 , hydroxyl claim 1 , or NH.8. The compound of any one of to claim 1 , wherein Ris hydrogen.9. The compound of any one of to claim 1 , wherein m is 1 and Ris deuterium claim 1 , optionally substituted C-Calkyl claim 1 , optionally substituted C-Calkenyl claim 1 , optionally substituted C-Calkynyl claim 1 , or Rand Rcombine with the atoms to which they are attached to form an optionally substituted C-Ccycloalkyl ring.10. The compound of claim 9 , wherein Ris deuterium.11. The compound of claim 10 , wherein Ris deuterium.12. The compound of or claim 10 , wherein Rand Rare both deuterium.13. The compound of claim 9 , wherein Ris optionally substituted C-Calkyl claim 9 , optionally substituted C-Calkenyl claim 9 , optionally substituted C-Calkynyl.14. The compound of claim 13 , wherein Ris methyl claim 13 , ethyl claim 13 , n-propyl claim 13 , iso-propyl claim 13 , —CD claim 13 , —CF claim 13 , —CHF claim 13 , —CHF claim 13 , —CH═CH claim 13 , or —C≡CH.15. The compound of or claim 13 , wherein Ris hydrogen or methyl.16. The compound of any one of to claim 13 , wherein Ris hydrogen.17. The compound of any one of to claim 13 , wherein Ris hydrogen claim 13 , NH claim 13 , or methyl.18. The compound of claim 9 , wherein Rand Rcombine with the atoms to which they are attached to form an optionally substituted C-Ccycloalkyl ring.19. The compound of claim 18 , wherein said optionally substituted C-Ccycloalkyl ring is an optionally substituted C-Ccycloalkyl ring.20. The ...

Подробнее
Номер записи: 56
26-02-2015 дата публикации

Method for preparation of medetomidine

Номер: US20150057453A1
Автор: Anna KULESZA, Florencio Zaragoza Doerwald, Krzysztof Wojciechowski, Robert BUJOK, Stephan Elzner, Zbigniew WROBEL
Принадлежит: Lonza AG

The invention discloses a method for the preparation of medetomidine starting from 1-bromo 2,3-dimethylbenzene and aceton.

Подробнее
Номер записи: 57
13-02-2020 дата публикации

ORGANIC COMPOUND, ORGANIC LIGHT-EMITTING DIODE AND ORGANIC LIGHT-EMITTING DEVICE CONTAINING THE COMPOUND

Номер: US20200052222A1
Автор: BAE Suk-Young, KIM Jun-Yun, SHIN In-Ae
Принадлежит: LG DISPLAY CO., LTD.

An organic compound having a spiro-anthracene core and an aromatic or heteroaromatic group and/or an amino group bonded to the core, and an organic light-emitting diode and an organic light-emitting device including the organic compound are disclosed. Since the organic compound of the present disclosure has a rigid structure and a substantially narrow full width at half maximum (FWHM), it is possible to manufacture an organic light-emitting diode and an organic light-emitting device with lowered driving voltages and enhanced luminous efficiency and color purity using the organic compound. 5. An organic light-emitting diode , comprising:a first electrode;a second electrode facing the first electrode; anda first emitting material layer between the first and second electrode,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the first emitting material layer includes an organic compound according to .'}6. The organic light-emitting diode of claim 5 , wherein the first emitting material layer further includes a first host claim 5 , wherein the organic compound is used as a first fluorescent dopant.7. The organic light-emitting diode of claim 5 , wherein the first emitting material layer further includes a first host and a first dopant claim 5 , wherein the organic compound is used as a second dopant.8. The organic light-emitting diode of claim 7 , wherein an excited state singlet energy level of the first dopant is higher than an excited state singlet energy level of the second dopant.9. The organic light-emitting diode of claim 7 , wherein an energy bandgap between an excited state singlet energy level of the first dopant and an excited state triplet energy level of the first dopant is equal to or less than about 0.3 eV.10. The organic light-emitting diode of claim 7 , an energy bandgap between a Highest Occupied Molecular Orbital energy level of the first host and a Highest Occupied Molecular Orbital energy level of the first dopant or an energy bandgap ...

Подробнее
Номер записи: 58
04-03-2021 дата публикации

Synthetic Nicotine Composition

Номер: US20210061783A1
Автор: Cao Yinghui, Chen Yuefeng, Chen Zheng, HUANG Zhennan, WANG Songfeng, YAN Ningning, YUAN Shenghong, Zhang Yong
Принадлежит:

A synthetic nicotine composition comprising synthetic nicotine, a synthetic nicotine salt and a synthetic nicotine derivative, wherein the synthetic nicotine, the synthetic nicotine salt, and the synthetic nicotine derivative are in mass percentage; the synthetic nicotine accounts for 1-20%, the synthetic nicotine salt accounts for 30-70%, and the synthetic nicotine derivative accounts for 20-50%; and the synthetic nicotine is one or more of S-nicotine and a mixture of R-nicotine containing a racemate and S-nicotine. The synthetic nicotine, synthetic nicotine salt and synthetic nicotine derivative according to the present invention are proportionally mixed to prepare an existing synthetic nicotine product, which relieves the problem of the impact of impurities in natural extracted nicotine products causing an unpleasant smell, a bitter taste and a strong volatility, and can be used in the fields of low temperature heat-not-burn products, snuff, electronic cigarettes, nicotine release patches, insecticides, herbicides, microbicides, drug synthesis, etc. 1. A synthetic nicotine composition comprising synthetic nicotine , a synthetic nicotine salt and a synthetic nicotine derivative , wherein the synthetic nicotine , the synthetic nicotine salt , and the synthetic nicotine derivative are in mass percentage; the synthetic nicotine accounts for 1-20% , the synthetic nicotine salt accounts for 30-70% , and the synthetic nicotine derivative accounts for 20-50%; the synthetic nicotine is one or more of S-nicotine and a mixture of R-nicotine containing a racemate and S-nicotine; the synthetic nicotine salt is formed by reacting the synthetic nicotine with an organic acid mixture; and the nicotine derivative comprises one or more of an imidazole derivative of nicotine , an amine derivative of nicotine , and an amino acid derivative of nicotine.2. The synthetic nicotine composition according to claim 1 , wherein the synthesis organic acid mixture for the synthetic nicotine ...

Подробнее
Номер записи: 59
20-02-2020 дата публикации

ANTI-FIBROTIC COMPOUNDS

Номер: US20200055814A1
Автор: Miller Thomas, Papaioannou Nikolaos
Принадлежит:

Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound KIN or composition described herein. (Formula (I)) 235-. (canceled)36. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , whereinG is hydrogen;m is H or 2; and{'sup': '6', 'each occurrence of Ris, independently, F or Cl.'}37. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein{'sup': '7', 'G is C(O)R;'}m is 0;{'sup': 7', '9, 'Ris NHR; and'}{'sup': '9', 'Ris tetrazolyl, pyridinyl, pyrazolyl, imidazolyl, or triazolyl, each of which is optionally substituted with up to two alkyl groups.'}40. The compound of claim 39 , or a pharmaceutically acceptable salt thereof claim 39 , whereinX is O;{'sup': '10', 'Y is NR; and'}{'sup': '10', 'sub': '1-4', 'Ris Calkyl.'}41. The compound of claim 39 , or a pharmaceutically acceptable salt thereof claim 39 , wherein{'sup': '10', 'X is NR; and'}Y is O.42. The compound of claim 39 , or a pharmaceutically acceptable salt thereof claim 39 , wherein Rand Rtogether with the carbon atom to which they are attached form a carbonyl.44. A compound selected from the group consisting of:(E)-N-(2-fluorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (1);(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(2-(5-methyl-1H-1,2,4-triazol-3-yl)phenyl)acrylamide (2);(E)-N-(2-chlorophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (3);(E)-N-(2-bromophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (4);(E)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)-N-(o-tolyl)acrylamide (5);(E)-N-(2-cyanophenyl)-3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamide (6);(E)-N-(3,4-dichlorophenyl)-3-(3- ...

Подробнее
Номер записи: 60
22-05-2014 дата публикации

AZOLIUM AND PURINIUM SALT ANTICANCER AND ANTIMICROBIAL AGENTS

Номер: US20140142307A1
Автор: Deblock Michael, Panzner Matthew, Robishaw Nikki, Tessier Claire, Wagers Patrick, Wright Brian, Youngs Wiley
Принадлежит:

Singly and multiply charged imidazolium cations (ICs) have been identified as a class of chemical compositions that possess potent antineoplastic, antibacterial and antimicrobial properties. The imidazolium cations disclosed demonstrate greater or equivalent potency towards cancerous cells as the current clinical standard, cisplatin. These imidazolium cations, however, achieve this efficacy without any of the known toxic side effects caused by heavy metal-based antineoplastic drugs such as cisplati. This application claims the benefit of U.S. Provisional Patent Application No. 61/480,410 filed Apr. 29, 2011, the disclosure of which is hereby incorporated by reference.This invention relates to compositions of antineoplastic azolium and purinium salts for the effective treatment of human cancers and microbial infections.Cancer is a broad group of diseases that are characterized by an uncontrolled growth and spread of abnormal cells. These cancerous cells are caused from a malfunction in the genes that control cell growth and division; this malfunction can be caused by both internal and external factors. According to the American Cancer Society one out of every 3 people will be diagnosed with cancer in their lifetime and will cause 1 out of every 4 deaths in the United States. The survival rate of those diagnosed has increased in recent years, in large part due to new chemotherapeutic agents. Cisplatin and Carboplatin are chemotherapeutic agents that have been widely used over the past 45 years to treat a large variety of cancers. These drugs are far from ideal because of their toxic side effects and the ability of cancers to develop resistance to them. There is a need to find new anticancer drugs that that less toxic is highly desirous.Another leading cause of human disease and mortality is microbial infection. Of particular concern are infections caused by microbes which have developed resistance to current antibiotics. According to the U.S. Food and Drug ...

Подробнее
Номер записи: 61
28-02-2019 дата публикации

SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Номер: US20190062300A1
Автор: Huang Hui, Kuo Gee-Hong, Player Mark R., Yang Shyh-Ming, Zhang Yue-Mei
Принадлежит:

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: 135-. (canceled)36. A compound selected from the group consisting of:Cpd 3, (3S)-3-[4-[[3-[4-[(4-Hydroxy-1,1-dioxo-thian-4-yl)methoxy]-2-methyl-phenyl]benzo[b]thiophen-5-yl]methoxy]phenyl]hex-4-ynoic acid;Cpd 5, (3S)-3-[4-[[3-[4-(1,1-Dioxo-1,4-thiazinane-4-carbonyl)-2-methyl-phenyl]benzo[b]thiophen-5-yl]methoxy]phenyl]hex-4-ynoic acid;Cpd 6, (3S)-3-[4-[[3-[4-(1,1-Dioxo-3,6-dihydro-2H-thiopyran-4-yl)-2-methyl-phenyl]benzo[b]thiophen-5-yl]methoxy]phenyl]hex-4-ynoic acid;Cpd 8, (3S)-3-[4-[[3-[4-(1,1-Dioxothian-4-yl)-2-methyl-phenyl]benzo[b]thiophen-5-yl]methoxy]phenyl]hex-4-ynoic acid;Cpd 9, (3S)-3-[4-[[3-[4-(1,1-Dioxothian-4-yl)oxy-2-methyl-phenyl]-2-methyl-benzo[b]thiophen-5-yl]methoxy]phenyl]hex-4-ynoic acid;Cpd 14, (3S)-3-(4-((3-(2-Methyl-4-((3-methyloxetan-3-yl)methoxy)phenyl)benzo[b]thiophen-5-yl)methoxy)phenyl)hex-4-ynoic acid;Cpd 15, (3S)-3-(4-((3-(2-Methyl-4-((tetrahydro-2H-pyran-4-yl)oxy)phenyl)benzo[b]thiophen-5-yl)methoxy)phenyl)hex-4-ynoic acid;Cpd 17, (3S)-3-(4-((3-(4-((1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)-2-methylphenyl)benzo[b]thiophen-5-yl)methoxy)phenyl)hex-4-ynoic acid;Cpd 18, (3S)-3-(4-((3-(2-Methyl-4-((3-methyl-1,1-dioxidothietan-3-yl)methoxy)phenyl)benzo[b]thiophen-5-yl)methoxy)phenyl)hex-4-ynoic acid;Cpd 22, (3S)-3-(4-((3-(2-Methylpyridin-3-yl)benzo[b]thiophen-5-yl)methoxy)phenyl)hex-4-ynoic acid;Cpd 25, (3S)-3-(4-(((3-(4-(1,1-Dioxido-3,6-dihydro-2H-thiopyran-4-yl)-2-methylphenyl)benzo[b]thiophen-5-yl)oxy)methyl)phenyl)hex-4-ynoic acid;Cpd 26, (3S)-3-(4-(((3-(4-(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)-2-methylphenyl)benzo[b]thiophen-5-yl)oxy)methyl)phenyl)hex-4-ynoic acid;Cpd 28, 2-(1-(4-((3-(4-(1,1-Dioxido-3,6-dihydro-2H-thiopyran-4-yl)-2-methylphenyl)benzo[b]thiophen-5-yl)methoxy)phenyl)-3-oxocyclobutyl)acetic acid;Cpd 29, 2-(1-(4-((3-(4-(1,1 ...

Подробнее
Номер записи: 62
10-03-2016 дата публикации

SYNERGISTIC COMPOSITIONS

Номер: US20160068484A1
Автор: Banerjee Kaushik, Giri Suresh, Jain Mukul R., Kachhiya Rashmikant, Kothari Himanshu M.
Принадлежит: CADILA HEALTHCARE LIMITED

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) 2. The synergistic composition as claimed in claim 1 , wherein the one or more DPP IV inhibitors are selected from Sitagliptin claim 1 , Vildagliptin claim 1 , Saxagliptin claim 1 , Alogliptin and Linagliptin.3. The synergistic composition as claimed in claim 1 , wherein the one or more statins are selected from Lovastatin claim 1 , Pravastatin claim 1 , Fluvastatin claim 1 , Simvastatin claim 1 , Atorvastatin claim 1 , Rosuvastatin and Pitavastatin.4. The synergistic composition as claimed in claim 1 , wherein the one or more biguanide antihyperglycaemic agents are selected from Metformin claim 1 , Buformin or Phenformin.5. The synergistic composition as claimed in claim 1 , wherein the one or more thiazolidinediones are selected from Pioglitazone and Rosiglitazone.6. The synergistic composition as claimed in claim 1 , wherein the one or more sulphonylureas are selected from glibenclamide claim 1 , glipizide claim 1 , gliclazide claim 1 , glimepiride claim 1 , tolazamide claim 1 , tolbutamide claim 1 , acetohexamide claim 1 , carbutamide claim 1 , chlorpropamide claim 1 , glibomuride claim 1 , gliquidone claim 1 , glisentide claim 1 , glisolamide claim 1 , glisoxepide claim 1 , glyclopyamide claim 1 , glycylamide and glipentide.7. The synergistic composition as claimed in claim 1 , wherein the one or more SGLT-2 inhibitors are selected from Dapagliflozin claim 1 , Canagliflozin claim 1 , Empagliflozin claim 1 , Ertugliflozin and Ipragliflozin.8. The synergistic composition as claimed in claim 1 , wherein the one or more GLP-1 agonists are selected from Exenatide claim 1 , Liraglutide and Dulaglutide.9. (canceled)10. A method for the treatment of dyslipidemia claim 1 , hypertriglyceridemia or diabetes mellitus which comprises ...

Подробнее
Номер записи: 63
29-05-2014 дата публикации

PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND ITS SALTS

Номер: US20140148601A1
Автор: Eswaraiah Sajja, Nagaraju Chakilam, Raghuram Suraparaju, Rajan Srinivasan Thirumalai, Ramprasad Achampeta Kodanda, Reddy Manne Satyanarayana
Принадлежит: MSN Laboratories Limited

An dabigatran etexilate intermediate of Formula-6a, and the use in the preparation of dabigatran etexilate thereof. 133.-. (canceled)35. The process according to claim 34 , wherein the suitable solvent used in step (a) is a chloro solvent claim 34 , ester solvent claim 34 , ether solvent claim 34 , ketone solvent or polar aprotic solvent; andthe solvent used in step (b) is ether solvent, ester solvent, ketone solvent, polar aprotic solvent or nitrile solvents;and the base is an alkali metal carbonate or an alkali metal bicarbonate.36. The process according to claim 34 , wherein the solvent used in step (a) is in an amount ranging from 2-10 volumes to 1 g of compound of Formula-5 or compound of Formula-6; andthe solvent used in step (b) is in an amount ranging from 5-50 volumes to 1 g of compound of Formula-5 or compound of Formula-6.37. The process according to claim 34 , wherein the mole proportions of base claim 34 , N claim 34 ,N-carbonyldiimidazole and n-hexanol are in an amount ranging between 0.8-10 claim 34 , 0.8-6 and 0.8-6 respectively claim 34 , per one mole of compound of Formula-5 or compound of Formula-6.39. The process according to wherein the compound of Formula-4 is used in step (b) without isolation.44. The compound according to claim 43 , wherein the oxalate salt compound of Formula-6a is a crystalline solid herein designated as crystalline form-M and is characterized by:{'figref': {'@idref': 'DRAWINGS', 'FIG. 1'}, 'a) its powder XRD pattern having peaks at about 7.6, 11.7, 14.5, 18.0, 18.2, 22.8, 24.8 and 25.3±0.2 degrees of two-theta as illustrated in ; or'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 2'}, 'b) its DSC thermogram showing endotherm at about 203.53° C. and as shown in .'}48. Dabigatran etexilate mesylate produced by the process of :a) having a purity greater than 99.50% by HPLC; orb) having a purity greater than 99.75% by HPLC; orc) having a purity greater than 99.95% by HPLC; ord) containing less than 0.05% of Impurity-X and Impurity-Y ...

Подробнее
Номер записи: 64
17-03-2016 дата публикации

CETP Inhibitors

Номер: US20160075724A1
Автор: Ali Amjad, Chen Yi-Heng, Deng Qiaolin, Dowst Adrian A., Hallet Gayle E., Hunt Julianne A., LI HONG, LU Zhijian, Napolitano Joann M., Quraishi Nazia, Sinclair Peter J., Smith Cameron J., Thompson Christopher F.
Принадлежит:

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: 221-. (canceled) This invention relates to a class of chemical compounds that inhibit cholesterol ester transfer protein (CETP) and therefore may have utility in the treatment and prevention of atherosclerosis.Atherosclerosis and its clinical consequences, coronary heart disease (CHD), stroke and peripheral vascular disease, represent a truly enormous burden to the health care systems of the industrialized world. In the United States alone, approximately 13 million patients have been diagnosed with CHD, and greater than one half million deaths are attributed to CHD each year. Further, this toll is expected to grow over the next quarter century as an epidemic in obesity and diabetes continues to grow.It has long been recognized that in mammals, variations in circulating lipoprotein profiles correlate with the risk of atherosclerosis and CHD. The clinical success of HMG-CoA Reductase inhibitors, especially the statins, in reducing coronary events is based on the reduction of circulating Low Density Lipoprotein cholesterol (LDL-C), levels of which correlate directly with increased risk for atherosclerosis. More recently, epidemiologic studies have demonstrated an inverse relationship between High Density Lipoprotein cholesterol (HDL-C) levels and atherosclerosis, leading to the conclusion that low serum HDL-C levels are associated with an increased risk for CHD.Metabolic control of lipoprotein levels is a complex and dynamic process involving many factors. One important metabolic control in man is the cholesteryl ester transfer protein (CETP), a plasma glycoprotein that catalyzes the movement of cholesteryl esters from HDL to the apoB containing lipoproteins, especially VLDL (see Hesler, C. B., et. al. (1987) 262(5), 2275-2282 ...

Подробнее
Номер записи: 65
19-03-2015 дата публикации

METHOD FOR PREPARATION OF 2-(2,3-DIMETHYLPHENYL)-1-PROPANAL

Номер: US20150080287A1
Автор: Bujok Robert, Elzner Stephan, KULESZA Anna, Wojciechowski Krzysztof, Wrobel Zbigniew, Zaragoza Doerwald Florencio
Принадлежит:

The invention discloses a method for preparation of 2-(2,3-dimethylphenyl)-1-proponal from bromo 2,3-dimethyl-benzene and aceton, its use in perfumes and its use for the preparation of medetomidine. 2. The method according to claim 1 , wherein the catalyst (N-cat) is selected from the group consisting of acetic acid claim 1 , formic acid claim 1 , trifluoroacetic acid claim 1 , methanesulfonic acid claim 1 , p-toluenesulfonic acid claim 1 , HCl claim 1 , HBr claim 1 , HSO claim 1 , HPO claim 1 , BCl claim 1 , BFOEt claim 1 , MgCl claim 1 , MgBr claim 1 , AlCl claim 1 , ZnCl claim 1 , Cu(BF) claim 1 , aluminosilicates claim 1 , acidic ion exchange resins claim 1 , carbon treated with HCl claim 1 , HSOor HNO claim 1 , and mixtures thereof.3. The method according to claim 1 , wherein reaction (N-reac) is done in a solvent (N-solv);solvent (N-solv) is selected from the group consisting of water, tert-butanol, isopropanol, acetonitrile, propionitrile, THF, methyl-THF, NMP, dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, chloroform, toluene, benzene, chlorobenzene, hexane, cyclohexane, ethyl acetate, acetic acid, formic acid, trifluoroacetic acid and mixtures thereof.5. The method according to claim 4 , wherein reagent (O-reag) is selected from the group consisting of peracetic acid claim 4 , tert-butylhydroperoxide claim 4 , oxygen claim 4 , air claim 4 , sodium hypochlorite claim 4 , aqueous HO claim 4 , HOdissolved in acetic acid claim 4 , HOdissolved in trifluoroacetic acid claim 4 , and mixtures thereof.8. Use of compound of formula (XXI) as a fragrance claim 1 , with the compound of formula (XXI) as defined in .9. Use of compound of formula (XXI) for the preparation of medetomidine claim 1 , with the compound of formula (XXI) as defined in . This application is the national stage entry of International Patent Application No. PCT/EP2012/072797 having a filing date of Nov. 15, 2012, which claims the filing benefit of European Patent Application No. ...

Подробнее
Номер записи: 66
05-06-2014 дата публикации

Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System

Номер: US20140155445A1
Автор: Alaoui-Jamali Moulay, Gupta Ajay, Nakatsu Kanji, Schipper Hyman M., Szarek Walter A., Vlahakis Jason Z.
Принадлежит:

Disclosed are compounds of the general formula (I): 132-. (canceled)3436-. (canceled)37. The method of claim 33 , wherein D is 1 claim 33 ,3-imidazolyl.38. The method of claim 33 , wherein n is 3 to 4.39. The method of claim 33 , wherein n is 4.40. The method of claim 33 , wherein T is substituted with perfluoroalkyl.41. The method of claim 33 , wherein T is selected from the group consisting of: 4-chlorophenyl claim 33 , 3-methoxyphenyl claim 33 , 2-amino-4-chlorophenyl claim 33 , 4-methoxyphenyl claim 33 , phenyl claim 33 , 4 fluorophenyl claim 33 , 4-bromophenyl claim 33 , 4-iodophenyl claim 33 , 2-hydroxyphenyl claim 33 , 4-nitrophenyl claim 33 , biphenyl-4-yl claim 33 , 3 claim 33 ,4-dichlorophenyl claim 33 , 4-isopropylphenyl claim 33 , 4-tert-butylphenyl claim 33 , 4-hydroxyphenyl claim 33 , 4-(trifluoromethyl)phenyl) claim 33 , and 4-benzoylphenyl.42. (canceled)43. The method of claim 33 , wherein said compound is selected from the group consisting of: 4-(4-chlorophenyl)-1-(1H-imidazol-1-yl)butane hydrochloride (QC-105); 1-(3-Phenyl-propyl)-1H-imidazole hydrochloride (QC-172); 1-[4-(4-Bromo-phenyl)-butyl]1H-imidazole hydrochloride (QC-199); 1-[4-(4-(Trifluoromethyl)phenyl)butyl]-1H-imidazole hydrochloride (QC-234); and pharmaceutically acceptable salts thereof.44. The method of claim 33 , wherein said compound is 1-[4-(4 Bromo-phenyl)-butyl]-1H-imidazole hydrochloride (QC-199); or pharmaceutically acceptable salts thereof.45. The method according to claim 33 , wherein the disease is Alzheimer's disease.4689-. (canceled)90. The method according to claim 33 , wherein the disease is Parkinson's disease.91. The method of claim 40 , wherein T is substituted with Br.92. The method of claim 40 , wherein T is substituted with Cl. This invention is in the field of pharmaceuticals, and relates to compounds and compositions for treating/mitigating cancer and for suppressing tumor growth. The invention also relates to compounds, compositions and methods for the ...

Подробнее
Номер записи: 67
18-03-2021 дата публикации

Dissolution of Cellulose in Ionic Liquids

Номер: US20210079593A1
Автор: Edward Quitevis, Niwanthi Dissanayake, Noureddine Abidi, Vidura D. Thalangamaarachchige
Принадлежит: Texas Tech University System

The present invention includes a method for dissolving cellulose comprising dissolving cellulose in an ionic liquid and a co-solvent, wherein the ionic liquid is an imidazolium-based ionic liquid with, e.g., a halide or acetate as the anion.

Подробнее
Номер записи: 68
24-03-2016 дата публикации

A PROCESS FOR REGENERATING IONIC COMPOUND

Номер: US20160082426A1
Автор: Aduri Pavankumar, DUKHANDE Vibhuti, Kotra Viswanath, RAJE Vivek Prabhakar, SAKHALKAR Mangesh, UPPARA Parasu Veera
Принадлежит: RELIANCE INDUSTRIES LIMITED

The present disclosure provides a process for regenerating the deactivated ionic compound. The process involves mixing a deactivated ionic compound with at least one solvent such as ethyl acetate and neutralizing with at least one base such as triethylamine and tert-butyl amine to obtain a precipitate. The obtained precipitate is filtered to obtain a residue which is then washed with a solvent such as dichloromethane to obtain the ionic compound. 2. The process as claimed in claim 1 , wherein Rand Rare independently selected from the group consisting of methyl claim 1 , ethyl claim 1 , propyl and butyl.3. The process as claimed in claim 1 , wherein the halogen is selected from the group consisting of bromine and chlorine.4. The process as claimed in claim 1 , wherein the metal chloride is aluminium trichloride.5. The process as claimed in claim 1 , wherein base is selected from the group consisting of triethylamine claim 1 , tert-butyl amine claim 1 , sodium carbonate claim 1 , sodium bicarbonate claim 1 , potassium carbonate claim 1 , potassium bicarbonate claim 1 , ammonium carbonate and combinations.6. The process as claimed in claim 1 , wherein the step (a) is carried out at a temperature ranging from 20° C. to 50° C.7. The process as claimed in claim 1 , include steps of recovering and recycling of ethyl acetate and dichloromethane.8. The process as claimed in claim 1 , wherein the step (a) includes adjusting the pH value in the range of 7 to 7.5.9. The process as claimed in claim 1 , wherein said process characterized in that the recovery of the ionic compound ranges from 60 to 99%. The present disclosure relates to a process for regenerating ionic compound. The present disclosure particularly relates to a process for regenerating halo metal based ionic compound.Ionic compounds are compounds that are composed of ions i.e., cations and anions. Ionic compounds are suitable for use as a catalyst and as a solvent in alkylation reactions, polymerization, ...

Подробнее
Номер записи: 69
24-03-2016 дата публикации

Compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action

Номер: US20160083355A1
Автор: Daniel Gillet, Julien Barbier, Roman Lopez, Severine Hebbe
Принадлежит: Commissariat a lEnergie Atomique et aux Energies Alternatives CEA

The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.

Подробнее
Номер записи: 70
12-03-2020 дата публикации

Carbonate derivative production method

Номер: US20200079723A1
Автор: Akihiko Tsuda
Принадлежит: Kobe University NUC, Mitsubishi Gas Chemical Co Inc

The objective of the present invention is to provide a method for producing a carbonate derivative in a safe and efficient manner. The method for producing a carbonate derivative according to the present invention is characterized in comprising irradiating light on a composition containing a C1-4 halogenated hydrocarbon having one or more kinds of halogen atoms selected from the group consisting of a chlorine atom, a bromine atom and an iodine atom, a nucleophilic functional group-containing compound and the specific base in the presence of oxygen.

Подробнее
Номер записи: 71
31-03-2022 дата публикации

Cooling Systems Having An Integrated Ionic Liquid Salt Dehumidification System

Номер: US20220099314A1
Автор: Abdelaziz Omar, Bahar Bamdad, Ming Qu, Parmelee William
Принадлежит:

A cooling system utilizes an organic ionic salt composition for dehumidification of an airflow. The organic ionic salt composition absorbs moisture from an inlet airflow to produce an outlet airflow with a reduce moisture from that of the inlet airflow. The organic ionic salt composition may be regenerated, wherein the absorbed moisture is expelled by heating with a heating device. The heating device may be an electrochemical heating device, such as a fuel cell, an electrochemical metal hydride heating device, an electrochemical heat pump or compressor, or a condenser of a refrigerant cycle, which may utilize an electrochemical pump or compressor. The efficiency of the cooling system may be increased by utilization of the waste heat the cooling system. The organic ionic salt composition may circulate back and forth or in a loop between a conditioner, where it absorbs moisture, to a regenerator, where moisture is desorbed by heating. 1. A cooling system comprising an ionic liquid dehumidification system comprising:{'claim-text': ['i) an ionic liquid desiccant;', 'ii) water;'], '#text': 'a) an ionic liquid desiccant composition comprising:'}{'claim-text': [{'claim-text': ['an ionic liquid desiccant inlet;', 'an ionic liquid desiccant outlet;'], '#text': 'i) a conditioner ionic liquid desiccant conduit having:'}, 'wherein the ionic liquid desiccant composition flows through the conditioner ionic liquid desiccant conduit;', {'claim-text': ['a conditioner fluid inlet;', 'a conditioner fluid outlet;'], '#text': 'ii) a conditioner fluid conduit having:'}, 'wherein a conditioner fluid flows through the conditioner fluid conduit; and', 'iii) an impermeable exchange membrane configured between the conditioner ionic liquid desiccant conduit and the conditioner fluid conduit;', 'wherein the conditioner fluid comprises moisture that is transferred through the conditioner impermeable exchange membrane to the ionic liquid desiccant flowing through the conditioner ionic liquid ...

Подробнее
Номер записи: 72
29-03-2018 дата публикации

Novel 5-substituted imidazole derivatives

Номер: US20180084780A1
Автор: Bernier David, BRUNET Stephane, Coqueron Pierre-Yves, Dahmen Peter, Genix Pierre, HELMKE Hendrik, Hoffmann Sebastian, KENNEL Philippe, Meissner Ruth, MILLER Ricarda, NAUD Sebastien, Vors Jean-Pierre, Wachendorff-Neumann Ulrike, WITTROCK Sven
Принадлежит:

The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. 5. Method for controlling harmful microorganisms in crop protection and in the protection of one or more materials claim 1 , comprising applying a compound of the formula (I) and/or a salt and/or N-oxide thereof according to to the harmful microorganisms and/or a habitat thereof.6. Method for controlling phytopathogenic harmful fungi in crop protection and in the protection of one or more materials claim 1 , comprising applying a compound of the formula (I) and/or a salt and/or N-oxide thereof according to to the phytopathogenic harmful fungi and/or a habitat thereof.7. Composition for controlling harmful microorganisms claim 1 , optionally for controlling phytopathogenic harmful fungi claim 1 , comprising a content of at least one compound of the formula (I) and/or a salt and/or N-oxide thereof according to claim 1 , in addition to one or more extenders and/or surfactants.8. Composition according to comprising at least one further active ingredient selected from the group consisting of insecticides claim 7 , attractants claim 7 , sterilants claim 7 , bactericides claim 7 , acaricides claim 7 , nematicides claim 7 , fungicides claim 7 , growth regulators claim 7 , herbicides claim 7 , fertilizers claim 7 , safeners and semiochemicals.9. A product comprising a compound of the formula (I) and/or a salt and/or N-oxide thereof according to for control of harmful microorganisms claim 1 , optionally phytopathogenic harmful fungi claim 1 , in crop protection and/or for protection of one or more materials.10. Process for producing a composition for controlling harmful microorganisms claim 1 , optionally for ...

Подробнее
Номер записи: 73
21-03-2019 дата публикации

NOVEL 5-SUBSTITUTED IMIDAZOLE DERIVATIVES

Номер: US20190082691A1
Автор: Bernier David, BRUNET Stephane, Coqueron Pierre-Yves, Dahmen Peter, Genix Pierre, HELMKE Hendrik, Hoffmann Sebastian, KENNEL Philippe, Meissner Ruth, MILLER Ricarda, NAUD Sebastien, Vors Jean-Pierre, Wachendorff-Neumann Ulrike, WITTROCK Sven
Принадлежит:

The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. 2. A compound of formula (XVII) and/or a salt and/or N-oxide thereof according to claim 1 , wherein{'sup': '1', 'sub': 1', '8', '1', '8', '2', '7', '2', '7', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '3', '7, 'Rrepresents in each case optionally branched C-C-alkyl, C-C-haloalkyl, C-C-alkenyl, C-C-haloalkenyl, or optionally halogen-, cyano-, C-C-alkyl-, C-C-haloalkyl-, C-C-alkoxy-, C-C-haloalkoxy-, C-C-alkylthio- or C-C-haloalkylthio-substituted C-C-cycloalkyl.'}3. A compound of formula (XVII) and/or a salt and/or N-oxide thereof according to claim 1 , wherein{'sup': '1', 'sub': 1', '4', '1', '4', '2', '5', '2', '5', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '3', '6, 'Rrepresents in each case optionally branched C-C-alkyl, C-C-haloalkyl, C-C-alkenyl, C-C-haloalkenyl, or optionally halogen-, cyano-, C-C-alkyl-, C-C-haloalkyl-, C-C-haloalkoxy-, C-C-alkoxy-, C-C-alkylthio- or C-C-haloalkylthio-substituted C-C-cycloalkyl.'}4. A compound of formula (XVII) and/or a salt and/or N-oxide thereof according to claim 1 , wherein{'sup': '1', 'sub': 1', '4', '1', '4', '1', '4, 'Rrepresents tert-butyl, isopropyl, 1-halocyclopropyl, 1-(C-C-alkyl)cyclopropyl, 1-(C-C-alkoxy)cyclopropyl or 1-(C-C-alkylthio)cyclopropyl.'}5. A compound of formula (XVII) and/or a salt and/or N-oxide thereof according to claim 1 , wherein{'sup': '1', 'Rrepresents tert-butyl, isopropyl, 1-chlorocyclopropyl, 1-fluorocyclopropyl or 1-methylcyclopropyl.'}6. A compound of formula (XVII) and/or a salt and/or N-oxide thereof according to claim 1 , wherein{'sup': '1', 'Rrepresents 1-chlorocyclopropyl or 1-fluorocyclopropyl ...

Подробнее
Номер записи: 74
30-03-2017 дата публикации

Arginine methyltransferase inhibitors and uses thereof

Номер: US20170088529A1
Автор: Gideon Shapiro, Lorna Helen Mitchell, Richard Chesworth
Принадлежит: Epizyme Inc

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

Подробнее
Номер записи: 75
05-05-2022 дата публикации

PROCESSES FOR PREPARING ASK1 INHIBITORS

Номер: US20220135527A1
Автор: Brown Brandon Heath, Reynolds Troy Eva
Принадлежит:

The present disclosure provides processes for the preparation of a compound of formula:

Подробнее
Номер записи: 76
19-03-2020 дата публикации

Electrochemical methods, devices and compositions

Номер: US20200087812A1
Автор: Daniel A. KONOPKA, Jason A. SEEDIG
Принадлежит: Iontra Inc

The disclosure provides a method comprising inducing a first current between a source of a countercharge and a first electrode, the first current being through an electrolyte. In some instances, the first current is not present. A second current, in the form of waveform, is induced across the first electrode, the second current being transverse to the first current, and the second current inducing a relativistic charge across the first electrode. Metal from the electrolyte is deposited on the substrate or corroded from the substrate, among other things. The methods, as well as associated apparatus, improve deposition, bonding, corrosion, and other effects.

Подробнее
Номер записи: 77
09-04-2015 дата публикации

METHOD FOR PREPARATION OF MEDETOMIDINE WITH CHLOROACETONE

Номер: US20150099889A1
Автор: Bujok Robert, Elzner Stephen, KULESZA Anna, Wojciechowski Krzysztof, Wrobel Zbigniew, Zaragoza Doerwald Florencio
Принадлежит:

The invention discloses a method for the preparation of medetomidine starting from 1-bromo 2,3-dimethylbenzene and chloroacetone. 2. The method according to claim 1 , wherein step (M1) comprises two consecutive steps claim 1 , a first step (M1-A1-1) and a second step (M1-A1-2);step (M1-A1-1) comprises a reaction (M1-A1-1);reaction (M1-A1-1) is a reaction of a compound of formula (XXI) with reagent (M-reag) in the presence of a compound (M-comp) in a solvent (M-solv) to provide a reaction product of reaction (M1-A1-1);step (M1-A1-2) comprises a reaction (M1-A1-2);reaction (M1-A1-2) is a reaction of the reaction product of reaction (M1-A1-1) with a reagent (M-A) in a solvent (M-solv).3. The method according to claim 1 , wherein reagent (M-reag) is selected from the group consisting of p-toluenesulfonylmethyl isocyanide claim 1 , benzenesulfonylmethyl isocyanide and mixtures thereof.4. The method according to claim 1 , wherein reagent (M-A) is selected from the group consisting of ammonia claim 1 , sulfamic acid claim 1 , p-toluenesulfonamide claim 1 , benzenesulfonamide claim 1 , 4-acetamidobenzenesulfonamide claim 1 , tritylamine claim 1 , formamide and mixtures thereof.5. The method according to claim 1 , wherein solvent (M-solv) is selected from the group consisting of N claim 1 ,N-dimethylformamide claim 1 , methanol claim 1 , ethanol claim 1 , n-propanol claim 1 , isopropanol claim 1 , butanol claim 1 , pentanol claim 1 , hexanol claim 1 , water claim 1 , formamide claim 1 , 1 claim 1 ,2-dimethoxyethane claim 1 , NMP claim 1 , toluene claim 1 , acetonitrile claim 1 , propionitrile claim 1 , ethyl carbamate claim 1 , N claim 1 ,N-dimethylacetamide claim 1 , acetamide and mixtures thereof.6. The method according to claim 1 , wherein reaction (M1-reac) is done in the presence of a compound (M-comp) claim 1 , compound (M-comp) is selected from the group consisting of ammonia claim 1 , tritylamine claim 1 , NaCN claim 1 , KCN claim 1 , piperidine claim 1 , DBU claim 1 ...

Подробнее
Номер записи: 78
05-04-2018 дата публикации

COMPOUNDS FOR TREATMENT OF CANCER

Номер: US20180093971A1
Автор: Ahn Sunjoo, CHEN Jianjun, Dalton James T., Li Chien-Ming, Li Wei, Miller Duane D.
Принадлежит:

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer. 2. The method of claim 1 , wherein said cancer is selected from the group consisting of prostate cancer claim 1 , drug-resistant prostate cancer claim 1 , breast cancer claim 1 , ovarian cancer claim 1 , drug-resistant ovarian cancer claim 1 , skin cancer claim 1 , melanoma claim 1 , drug-resistant melanoma claim 1 , lung cancer claim 1 , colon cancer claim 1 , glioma claim 1 , leukemia claim 1 , lymphoma claim 1 , renal cancer claim 1 , CNS cancer claim 1 , uterine cancer claim 1 , drug-resistant uterine cancer claim 1 , and combinations thereof.3. The method of claim 2 , wherein said cancer is melanoma cancer.4. The method of claim 2 , wherein said cancer is metastatic melanoma.5. The method of claim 2 , wherein said cancer is prostate cancer.6. The method of claim 5 , wherein said prostate cancer is drug-resistant prostate cancer.7. The method of claim 2 , wherein said cancer is ovarian cancer.8. The method of claim 7 , wherein said ovarian cancer is drug-resistant ovarian cancer.9. The method of claim 2 , wherein said cancer is uterine cancer.10. The method of claim 9 , wherein said uterine cancer is drug-resistant uterine cancer.11. The method of claim 2 , wherein said cancer is lung cancer.12. The method of claim 2 , wherein said cancer is colon cancer.13. The method of claim 2 , wherein said administering is carried out in combination with another cancer therapy.15. The method of claim 14 , wherein said tumor is a melanoma cancer tumor.16. The method of claim 14 , wherein said tumor is a metastatic melanoma tumor.17. The method of claim 14 , wherein said tumor is a prostate cancer tumor.18. The method of claim 14 , wherein said tumor is an ovarian cancer tumor.19. The method of claim 14 , wherein said ...

Подробнее
Номер записи: 79
28-03-2019 дата публикации

COMPOUNDS FOR TREATMENT OF CANCER

Номер: US20190092755A1
Автор: Ahn Sunjoo, CHEN Jianjun, Dalton James T., Li Chien-Ming, Li Wei, Miller Duane D.
Принадлежит:

The present invention relates to a compound of formula XXII and a compound of formula 17ya, which are defined as anywhere in the specification, to a composition comprising the same, and to a method of using thereof in the treatment of various forms of cancer. 1. A compound selected from the following group:(2-(1-H-indol-1-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone;(2-(1-H-indol-2-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone;(2-(1-H-indol-4-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone;(2-(1-H-indol-5-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone;(2-(1-H-indol-6-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone; and(2-(1-H-indol-7-yl)imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone,or a pharmaceutically acceptable salt thereof, a hydrate thereof, or a combination thereof.2. A pharmaceutical composition comprising a compound according to and a pharmaceutically acceptable carrier.3. A compound according to for use as a medicament.4. Use of a compound of claim 1 , for the preparation of a medicament for treating prostate cancer claim 1 , breast cancer claim 1 , ovarian cancer claim 1 , skin cancer claim 1 , lung cancer claim 1 , colon cancer claim 1 , leukemia claim 1 , renal cancer or CNS cancer claim 1 , or a combination thereof.5. The use according to claim 4 , wherein the medicament is administered systemically.6. The use according to claim 4 , wherein the medicament is administered orally claim 4 , topically claim 4 , transdermally claim 4 , parenterally claim 4 , subcutaneously claim 4 , intravenously claim 4 , intramuscularly claim 4 , intraperitoneally claim 4 , by intranasal instillation claim 4 , by intracavitary or intravesical instillation claim 4 , intraocularly claim 4 , intraarterially claim 4 , intralesionally claim 4 , or by application to mucous membranes.7. The use according to claim 4 , wherein the medicament is administered directly to a site where cancer cells are present.8. The use according to claim 4 , wherein the ...

Подробнее
Номер записи: 80
14-04-2016 дата публикации

Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes

Номер: US20160102071A1
Автор: Gee-Hong Kuo, Hui Huang, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
Принадлежит: Janssen Pharmaceutica NV

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , R 5 , R 6 , W, and A are defined herein.

Подробнее
Номер записи: 81
12-04-2018 дата публикации

ANESTHETIC COMPOUNDS AND RELATED METHODS OF USE

Номер: US20180098968A1
Автор: HUSAIN Syed Shaukat, Raines Douglas E., RANDLE John C.R.
Принадлежит:

Provided herein are compounds according to formula (I): 197-. (canceled)99. The compound of claim 98 , wherein Z is N.100. The compound of claim 98 , wherein T is morpholinyl claim 98 , oxazolindinyl or oxetanyl.101. The compound of claim 98 , wherein T is methyl or ethyl.102. The compound of claim 98 , wherein Ris methyl claim 98 , ethyl claim 98 , n-propyl claim 98 , isopropyl claim 98 , butyl claim 98 , sec-butyl claim 98 , iso-butyl claim 98 , tert-butyl claim 98 , pentyl claim 98 , neopentyl claim 98 , hexyl claim 98 , 2-methylpentyl claim 98 , 3-methylpentyl claim 98 , 2 claim 98 ,3-dimethylbutyl claim 98 , or 2 claim 98 ,2-dimethylbutyl.103. The compound of claim 98 , wherein Rand Rare hydrogen.104. The compound of claim 98 , wherein Rand Rare hydrogen.105. The compound of claim 98 , wherein one of Rand Ris hydrogen and the other is optionally substituted aryl or optionally substituted heteroaryl.106. The compound of claim 98 , wherein n is 0.107. The compound of claim 98 , wherein Lis a bond.108. The compound of claim 98 , wherein Lis a bond.109. The compound of claim 98 , wherein n is 0; Land Lare a bond; Ris a C-Calkyl; and Rand R claim 98 , and Rare hydrogen.111. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable excipient.112. A method for providing anesthesia or sedation to a subject comprising administering to the subject a therapeutically effective amount of a compound of .113. The method of claim 112 , wherein the compound is administered intravenously.114. The method of claim 113 , wherein the compound is administered as a single intravenous bolus claim 113 , as a continuous intravenous infusion claim 113 , or a combination thereof.115. The method of claim 112 , wherein the subject is human.116. The method of claim 112 , wherein the compound is administered in a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.117. The method of claim 112 , further comprising administering ...

Подробнее
Номер записи: 82
12-04-2018 дата публикации

Apoptosis signal-regulating kinase inhibitor

Номер: US20180099950A1
Автор: Gregory Notte
Принадлежит: Gilead Sciences Inc

The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.

Подробнее
Номер записи: 83
21-04-2016 дата публикации

Heterocyclic derivatives and use thereof

Номер: US20160108056A1
Автор: Bu Young Choi, Byungho Kim, Chan Hee Park, Hoe Moon Kim, Jongmin Kim, Junhwan IM, Kwang Seok Ko, Sang Hwi Lee, Seunghee Kim, Soon Ok Lee, Sung Hyun Moon
Принадлежит: C&C RESEARCH LABORATORIES

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

Подробнее
Номер записи: 84
03-07-2014 дата публикации

NEW PROCESSES FOR PREPARING 4-SUBSTITUTED IMIDAZOLES

Номер: US20140187789A1
Автор: Eek Margus, Eklund Lars, HANSSON Lars, Holmberg Par, Lundholm Tommy
Принадлежит: CAMBREX KARLSKOGA AB

There is provided a novel process for the preparation of a compound of formula (I), (Formula (I)). There is also provided novel processes to intermediates of the compound of formula (I), as well as novel intermediates themselves. 2. A process as claimed in claim 1 , wherein:(a) the process is performed in the presence of formamidine, formamidine acetate, formamidine hydrohalide, formamidinesulfinic acid, or a mixture of ammonium chloride and formic acid; and/or{'sup': '2', '(b) Lrepresents a halo group, a sulfonate group, or an oxy-acyl group.'}3. A process as claimed in or claim 1 , wherein:(i) the process is performed in the presence of formamidine acetate; and/or{'sup': '1', '(ii) Lrepresents bromo.'}6. A process as claimed in claim 5 , wherein the bromination is performed in the presence of 5 claim 5 ,5-dibromo barbituric acid.7. A process as claimed in claim 5 , wherein the reaction is performed in the presence of a compound of formula IIIa claim 5 ,{'br': None, 'sup': a', 'b, 'HN(R)R\u2003\u2003IIIa'}wherein:{'sup': a', 'b, 'sub': 1-6', '1-6, 'Rand Rboth independently represent a Calkyl group optionally substituted with one or more substituents selected from halo, —CN and Calkoxy (wherein the latter group is optionally substituted with one or more fluoro atoms), or'}{'sup': a', 'b', 'c, 'Rand Rmay be taken together to form, together with the nitrogen atom to which they are both attached, a 5- to 6-membered heterocycloalkyl group, optionally containing one or two additional heteroatom-containing groups selected from O, S and NR'}{'sub': 1-6', '1-6, 'and optionally substituted with one or more substituents selected from halo, —CN, C, alkyl and Calkoxy (wherein the latter two groups are optionally substituted with one or more fluoro atoms); and'}{'sup': 'c', 'sub': 1-6', '1-6, 'Rrepresents H or a Calkyl group, wherein the latter group is optionally substituted with one or more substituents selected from halo, —CN and Calkoxy (wherein the latter group is ...

Подробнее
Номер записи: 85
20-04-2017 дата публикации

Pesticidally active heterocyclic derivatives with sulphur containing substituents

Номер: US20170107201A1
Автор: André Stoller, Andrew Edmunds, Anke Buchholz, Daniel EMERY, Michel Muehlebach, Peter Renold, Pierre Joseph Marcel Jung, Ruud Titulaer
Принадлежит: SYNGENTA PARTICIPATIONS AG

Compounds of formula (I), wherein the substituents are as defined in claim 1 , and the agrochemically acceptable salts salts, stereoismers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.

Подробнее
Номер записи: 86
30-04-2015 дата публикации

CORROSION INHIBITION COMPOSITION FOR PIPELINES, PROCESS OF ELABORATION AND SYNTHESIS

Номер: US20150118104A1
Автор: BENITEZ AGUILAR Jose Luis Rodolfo, CASTILLO CERVANTES Salvador, ESTRADA MARTINEZ Arquimedes, MARIN CRUZ Jesus, MARTINEZ PALOU Rafael, MONTIEL SANCHEZ Luisa Elena, QUEJ AKE Luis Manuel, SANCHEZ GARCIA Veronica, VEGA PAZ Araceli
Принадлежит:

Compounds and compositions are used as corrosion inhibitors for pipelines for crude oil containing water with high salt concentrations. The inhibitors are ionic liquids, imidazoles, benzotriazoles, and mixtures thereof. The composition includes two or more members of the inhibitors with a solvent. The inhibitors reduce corrosion of metallic surfaces of the pipelines containing crude oil having 0.2 and 40 wt % water, 10,000 to 70,000 ppm salt, and 9 to 600 ppm hydrogen sulfide. A synergic effect is provided by two or more different inhibitors. This synergy is derived from interactions with the metallic surface, among themselves or with the corrosive medium depending on the chain length, to inhibit the corrosion with decrease of the formulation dose. The composition can be a ternary formulation of the three families or two components of one family and a third component of a different family. 1. A corrosion inhibition composition for pipelines , process of elaboration and synthesis , wherein the procedure for obtaining each formulation comprises the following stages: a stage of synthesis of structures used as an active component; a step of addition of one , two or three active components of the same family or of different chemical structure family; a step of incorporating a solvent and a stirring stage until full integration of the formulation is achieved.2. A corrosion inhibition composition according to claim 1 , wherein the inhibitors are basically constituted by compounds of molecular structure families claim 1 , selected from the group consisting of imidazoles claim 1 , benzotriazoles and ionic liquids; the formulations including two or more components of each family and use as alcohol solvents claim 1 , xylene claim 1 , toluene claim 1 , or combinations thereof.3. A corrosion inhibition composition according to claim 1 , wherein it controls the corrosion of metallic surfaces of the pipelines containing congenital water concentrations from 0.2 to 40% by weight; ...

Подробнее
Номер записи: 87
09-06-2022 дата публикации

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

Номер: US20220175928A1
Автор: Akinc Akin, Jayaraman Muthusamy, Kandasamy Pachamuthu, MAIER Martin, Manoharan Muthiah, Matsuda Shigeo, Rajeev Kallanthottathil G.
Принадлежит:

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. 119-. (canceled)21. The lipid particle of claim 20 , wherein the biodegradable group is an ester.22. The lipid particle of claim 20 , wherein the head group comprises an aliphatic group and a hydroxyl group.23. The lipid particle of claim 20 , wherein the head group consists of a saturated aliphatic group and a hydroxyl group.24. The lipid particle of claim 20 , wherein the hydrophobic tails have different chemical formulas.25. The lipid particle of claim 20 , wherein claim 20 , in each hydrophobic tail claim 20 , Ris a saturated claim 20 , straight-chain C-Calkyl group.26. The lipid particle of claim 20 , wherein claim 20 , in each hydrophobic tail claim 20 , Ris n-hexyl.27. The lipid particle of claim 20 , wherein claim 20 , in each hydrophobic tail claim 20 , Ris branched.28. The lipid particle of claim 21 , wherein the ester group in each hydrophobic tail is —OC(O)—.29. The lipid particle of claim 21 , wherein the ester group in each hydrophobic tail is —C(O)O—.30. The lipid particle of claim 20 , wherein claim 20 , in each hydrophobic tail claim 20 , Ris a saturated claim 20 , branched C-Calkyl group claim 20 , where the branching occurs at the α-position relative to the biodegradable group claim 20 , and where the total carbon atom content of the tail is 21 to 26.31. The lipid particle of claim 20 , wherein claim 20 , in the at least one hydrophobic tail claim 20 , the biodegradable group is separated from a ...

Подробнее
Номер записи: 88
09-06-2022 дата публикации

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

Номер: US20220175929A1
Автор: Akinc Akin, Jayaraman Muthusamy, Kandasamy Pachamuthu, MAIER Martin, Manoharan Muthiah, Matsuda Shigeo, Rajeev Kallanthottathil G.
Принадлежит:

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. 119-. (canceled)20. A pharmaceutical composition comprising a lipid particle and a pharmaceutically acceptable diluent , wherein the lipid particle comprises:(i) a nucleic acid;(ii) 35-65 mol % of a lipid compound;(iii) 3-12 mol % of distearoylphosphatidylcholine (DSPC);(iv) 15-45 mol % of cholesterol; and(v) 0.5-10 mol % of 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoyl glycerol (PEG-DMG) having an average molecular weight of 2,000 Da, wherein the lipid compound comprises a head group, two hydrophobic tails, and a central moiety to which the head group and the two hydrophobic tails are directly bonded, wherein:the central moiety is a nitrogen atom;{'sup': 12', '1', '13', '12', '1', '13, 'sub': 4', '14', '10', '20, 'each of the two hydrophobic tails independently has the formula —R-M-R, wherein Ris a C-Calkyl group, Mis a biodegradable group, and Ris a C-Calkyl group;'}in each hydrophobic tail, the biodegradable group is separated from a terminus of the hydrophobic tail by from 8 to 12 carbon atoms; and{'sup': '13', 'in at least one hydrophobic tail, Ris branched, where the branching occurs at the α-position relative to the biodegradable group, and where the total carbon atom content of the at least one tail is 21 to 26.'}21. The pharmaceutical composition of claim 20 , wherein the nucleic acid comprises RNA.22. The pharmaceutical composition of claim 20 , further comprising sodium acetate.23. The pharmaceutical ...

Подробнее
Номер записи: 89
09-06-2022 дата публикации

BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS

Номер: US20220175930A1
Автор: Akinc Akin, Jayaraman Muthusamy, Kandasamy Pachamuthu, MAIER Martin, Manoharan Muthiah, Matsuda Shigeo, Rajeev Kallanthottathil G.
Принадлежит:

The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. 119-. (canceled)20. A pharmaceutical composition comprising a lipid particle and a pharmaceutically acceptable diluent , wherein the lipid particle comprises:(i) a nucleic acid;(ii) 35-65 mol % of a lipid compound;(iii) 3-12 mol % of distearoylphosphatidylcholine (DSPC);(iv) 15-45 mol % of cholesterol; and(v) 0.5-10 mol % of a PEG-modified lipid, whereinthe lipid compound comprises a head group, two hydrophobic tails, and a central moiety to which the head group and the two hydrophobic tails are directly bonded, wherein:the central moiety is a nitrogen atom;{'sup': 12', '1', '13', '12', '1', '13, 'sub': 4', '14', '10', '20, 'each of the two hydrophobic tails independently has the formula —R-M-R, wherein Ris a C-Calkyl group, Mis a biodegradable group, and Ris a C-Calkyl group;'}in each hydrophobic tail, the biodegradable group is separated from a terminus of the hydrophobic tail by from 8 to 12 carbon atoms; and{'sup': '13', 'in at least one hydrophobic tail, Ris branched, where the branching occurs at the α-position relative to the biodegradable group, and where the total carbon atom content of the at least one tail is 21 to 26.'}21. The pharmaceutical composition of claim 20 , wherein the nucleic acid comprises RNA.22. The pharmaceutical composition of claim 20 , wherein the pharmaceutical composition is a vaccine.23. The pharmaceutical composition of claim 20 , further comprising sodium chloride.24. The pharmaceutical ...

Подробнее
Номер записи: 90
30-04-2015 дата публикации

METHODS FOR REMOVING TRIAZINE FROM N-METHYLIMIDAZOLE FOR SYNTHESIS OF OLIGONUCLEOTIDE

Номер: US20150119564A1
Автор: Gajda Gregory, Lorenz Sandra M., Mohan Venkatraman
Принадлежит:

Methods for removing 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from a N-methylimidazole and methods for making oligonucleotides using N-methylimidazole are provided. In one embodiment, a method for removing 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from a feedstock containing N-methylimidazole includes contacting the feedstock with small or medium pore molecular sieves. The small or medium pore molecular sieves adsorb 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from the feedstock. The method further includes separating the small or medium pore molecular sieves from the feedstock. 1. A method for removing 1 ,3 ,5-trimethylhexahydro-1 ,3 ,5-triazine and N-methylenemethanamine from a feedstock containing N-methylimidazole , the method comprising:contacting the feedstock with small or medium pore molecular sieves, wherein the small or medium pore molecular sieves adsorb 1,3,5-trimethylhexahydro-1,3,5-triazine and N-methylenemethanamine from the feedstock; andseparating the small or medium pore molecular sieves from the feedstock.2. The method of wherein contacting the feedstock with small or medium pore molecular sieves comprises contacting the feedstock with synthetic molecular sieves having a pore aperture size of no more than about 0.6 nm.3. The method of wherein contacting the feedstock with small or medium pore molecular sieves comprises contacting the feedstock with silicoaluminophosphate (SAPO) molecular sieves.4. The method of wherein contacting the feedstock with small or medium pore molecular sieves comprises contacting the feedstock with SAPO-34 molecular sieves.5. The method of wherein contacting the feedstock with small or medium pore molecular sieves comprises:mixing the feedstock with the small or medium pore molecular sieves in a chamber,heating the chamber to form a reflux of condensed vapor, andreturning the reflux to the chamber.6. The method of further comprising the step of ...

Подробнее
Номер записи: 91
30-04-2015 дата публикации

Membrane Separation of Ionic Liquid Solutions

Номер: US20150119577A1
Автор: Campos Daniel, Feiring Andrew Edward, Majumdar Sudipto, Nemser Stuart
Принадлежит: CMS TECHNOLOGIES HOLDINGS, INC.

A membrane separation process using a highly fluorinated polymer membrane that selectively permeates water of an aqueous ionic liquid solution to provide dry ionic liquid. Preferably the polymer is a polymer that includes polymerized perfluoro-2,2-dimethyl-1,3-dioxole (PDD). The process is also capable of removing small molecular compounds such as organic solvents that can be present in the solution. This membrane separation process is suitable for drying the aqueous ionic liquid byproduct from precipitating solutions of biomass dissolved in ionic liquid, and is thus instrumental to providing usable lignocellulosic products for energy consumption and other industrial uses in an environmentally benign manner. 1. A method of separating an ionic liquid from a mixture comprising the steps of (i) providing the mixture that comprises ionic liquid and a liquid component selected from the group consisting of water , a small molecular compound and a blend thereof , (ii) providing a separator having a membrane comprising a selectively permeable , nonporous layer comprising a highly fluorinated polymer , through which membrane the liquid component transfers preferentially relative to the ionic liquid , (iii) providing a feed of the mixture in which the liquid component is present at an initial concentration , (iv) permeating components of the feed through the membrane , thereby selectively removing the liquid component from the feed , and (v) recovering from the membrane separator a liquid retentate product comprising the liquid component at a final concentration substantially lower than the initial concentration.2. The method of in which the ionic liquid is a compound selected from the group consisting of 1-allyl-3-methylimidazolium bis(trifluoromethanesulfonate) claim 1 , 1-ethyl-3-methylimidazolium acetate claim 1 , 1-ethyl-3-methylimidazolium chloride claim 1 , 1-ethyl-3-methylimidazolium bromide claim 1 , 1-ethyl-3-methylimidazolium tetrafluoroborate claim 1 , 1-ethyl-3- ...

Подробнее
Номер записи: 92
13-05-2021 дата публикации

CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF

Номер: US20210139433A1
Автор: Ma Bojun, NIU Deliang, Wan Qiang, ZHU Zhanqun
Принадлежит:

The present invention relates to a crystal form of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and the use thereof. Specifically, disclosed are a crystal form A of a monohydrochloride anhydrous substance of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride, a method for preparing the crystal form A and the use of the crystal form in the synthesis of nilotinib. The crystal form A of the present invention has good stability and purity, and can be directly used in the preparation and production of nilotinib. The method for preparing nilotinib in the present invention is easy to operate and has high industrial application value. 2. The crystal form A of claim 1 , wherein the X-ray powder diffraction pattern thereof further has 2θ value characteristic peaks at of 6.29±0.2° claim 1 , 18.93±0.2° claim 1 , 20.55±0.2° claim 1 , 29.28±0.2° claim 1 , 31.7±0.2°.3. The crystal form A of claim 1 , wherein the X-ray powder diffraction pattern of the crystal form A is substantially as shown in .4. The crystal form A of claim 1 , wherein the crystal form A starts to decompose when heated to 226±3° C.5. The crystal form A of claim 1 , wherein the crystal form A is an anhydrate claim 1 , and its moisture content is less than 0.50%.6. A method for preparing the crystal form A of claim 1 , wherein comprising the following steps:a) 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline free base is mixed with hydrochloric acid in an organic solvent;b) cooling and stirring to afford a suspension;c) filtering to collect the solid;d) the obtained solids are dried at 50-80° C. under 10-20 mmHg until the moisture content <0.5% to afford the crystal form A of the compound of formula (I).7. The preparation method of claim 6 , wherein the organic solvent is one or two selected from methanol claim 6 , toluene claim 6 , acetone.8. The preparation method of claim 6 , wherein the hydrochloric acid is 36%-38% hydrochloric acid claim 6 , and the ...

Подробнее
Номер записи: 93
04-05-2017 дата публикации

BULKY LIGANDS AND METAL COMPOUNDS COMPRISING BULKY LIGANDS

Номер: US20170121263A1
Автор: Marshak Michael Pesek
Принадлежит:

This disclosure provides, molecular metal catalysts supported by sterically bulky β-diketonate (acac) ligands. Disclosed herein are bulky β-diketonate ligands, methods of making bulky β-diketonate ligands, and methods of making metal catalysts supported by sterically bulky β-diketonate (acac) ligands. 4. The compound of claim 1 , having each of the groups X and Y bonded to a single metal atom;wherein said single metal atom is chosen from Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr, Ba, Sc, Y, La, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, Hf, Ta, W, Re, Os, Ir, Pt, Au, Al, Ga, In, TI, Ge, Sn, Pb, P, As, Sb, and Bi.5. The compound of claim 2 , having each of the groups X and Y bonded to a single metal atom;wherein said single metal atom is chosen from Li, Na, K, Rb, Cs, Be, Mg, Ca, Sr, Ba, Sc, Y, La, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, Hf, Ta, W, Re, Os, Ir, Pt, Au, Al, Ga, In, TI, Ge, Sn, Pb, P, As, Sb, and Bi.6. The compound of claim 3 , having each of the groups X and Y bonded to a single metal atom; wherein said single metal atom is chosen from Li claim 3 , Na claim 3 , K claim 3 , Rb claim 3 , Cs claim 3 , Be claim 3 , Mg claim 3 , Ca claim 3 , Sr claim 3 , Ba claim 3 , Sc claim 3 , Y claim 3 , La claim 3 , Ti claim 3 , V claim 3 , Cr claim 3 , Mn claim 3 , Fe claim 3 , Co claim 3 , Ni claim 3 , Cu claim 3 , Zn claim 3 , Zr claim 3 , Nb claim 3 , Mo claim 3 , Ru claim 3 , Rh claim 3 , Pd claim 3 , Ag claim 3 , Cd claim 3 , Hf claim 3 , Ta claim 3 , W claim 3 , Re claim 3 , Os claim 3 , Ir claim 3 , Pt claim 3 , Au claim 3 , Al claim 3 , Ga claim 3 , In claim 3 , TI claim 3 , Ge claim 3 , Sn claim 3 , Pb claim 3 , P claim 3 , As claim 3 , Sb claim 3 , and Bi. This disclosure relates to sterically bulky ligands for use in making metal catalysts and metal catalysts including sterically bulky ligands.Reactive molecular metal catalysts are an important class of molecules because they permit chemical transformations not ...

Подробнее
Номер записи: 94
16-04-2020 дата публикации

TETRALIN AND INDANE DERIVATIVES AND USES THEREOF

Номер: US20200115333A1
Автор: Greenhouse Robert, Harris, III Ralph New, Jaime-Figueroa Saul, Kress James M., Repke David Bruce, Stabler Russell Stephen
Принадлежит: Roche Palo Alto LLC

The application discloses pharmaceutical compounds of formula I useful for treating CNS diseases wherein m, s, RR, Rand Rare as defined herein. 2. The method of wherein m is 0 claim 1 , s is 1 claim 1 , Ris 3-fluoro claim 1 , Ris hydrogen and Ris acetyl claim 1 , aminocarbonyl or methylsulfonyl or a pharmaceutically acceptable salt.3. The method of wherein the compound is (R)-[6-(3-fluoro-benzenesulfonyl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydro-naphthalen-1-ylmethyl]-urea or a pharmaceutically acceptable salt.4. The method of claim 3 , wherein the central nervous system disease state is depression.5. The method of claim 3 , wherein the central nervous system disease state is a memory disorder.6. The method of claim 3 , wherein the central nervous system disease state is Parkinson's disease. This Application is a Continuation of U.S. application Ser. No. 15/597,478, filed May 17, 2017, which is a Continuation of U.S. application Ser. No. 14/531,465, filed Nov. 3, 2014, which is a Continuation U.S. application Ser. No. 13/314,525, filed on Dec. 8, 2011, which is a Continuation of U.S. application Ser. No. 11/985,459, filed on Nov. 15, 2007, which is a continuation of U.S. patent application Ser. No. 11/315,706, filed Dec. 21, 2005, which claims the benefit under Title 35 U.S.C. 119(e) of U.S. Provisional Patent Application Ser. No. 60/638,030, filed Dec. 21, 2004, the disclosure of which is incorporated herein by reference in its entirety.This invention relates to substituted indane and tetralin compounds, and associated compositions, methods for use as therapeutic agents, and methods of preparation thereof.The actions of 5-hydroxytryptamine (5-HT) as a major modulatory neurotransmitter in the brain are mediated through a number of receptor families termed 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HTS, 5-HT6, and 5-HT7. Based on a high level of 5-HT6 receptor mRNA in the brain, it has been stated that the 5-HT6 receptor may play a role in the pathology and treatment of ...

Подробнее
Номер записи: 95
27-05-2021 дата публикации

A PROCESS FOR SEPARATION OF HEAVY METALS AND/OR SULFUR SPECIES FROM IONIC LIQUIDS

Номер: US20210154618A1
Автор: Barnea Eyal, Barnea Zach, Yadid Sarit
Принадлежит:

Provided herein a process for purification of an ionic liquid from heavy metals, comprising combining heavy metal-containing ionic liquid and a sulfide source to form heavy metal sulfide, and separating said heavy metal sulfide from the ionic liquid. 1. A process for purification of an ionic liquid from heavy metals , comprising combining heavy metal-containing ionic liquid and a sulfide source to form heavy metal sulfide , and separating said heavy metal sulfide from the ionic liquid.2. The process according to claim 1 , wherein the ionic liquid contains the heavy metal in the form of a halide salt prior to the addition of the sulfide source.3. The process according to claim 1 , wherein said sulfide source is hydrogen sulfide claim 1 , ammonium sulfide claim 1 , or an alkali metal sulfide.4. The process according to claim 1 , wherein the heavy metal sulfide is separated from an essentially water-free ionic liquid.5. The process according to claim 4 , wherein the heavy metal sulfide is precipitated in claim 4 , and separated from claim 4 , an ionic liquid that comprises no more than 5 weight percent of water.6. The process according to claim 1 , wherein the heavy metal sulfide is separated from an aqueous ionic liquid mixture claim 1 , wherein the aqueous ionic liquid mixture is generated by diluting the ionic liquid with water subsequent to the addition of the sulfide source.7. The process according to claim 6 , wherein water is added to a concentration of between 25 and 60 weight percent in the aqueous ionic liquid mixture.8. The process according to claim 1 , wherein the heavy metal is mercury and the ionic liquid is 1-alkyl-3-methylimidazolium halide.9. A process of regeneration of spent scrubbing liquid suitable for removal of heavy metals from a gas claim 1 , wherein said spent liquid comprises an ionic liquid claim 1 , a heavy metal species and a reduced oxidant species claim 1 , said process comprises sequentially combining said spent scrubbing liquid with a ...

Подробнее
Номер записи: 96
12-05-2016 дата публикации

1,3-DIAMINOCYCLOPENTANE CARBOXAMIDE DERIVATIVES

Номер: US20160130214A1
Автор: CZODROWSKI Paul, Fuchss Thomas, Leuthner Birgitta, Staehle Wolfgang, Tsaklakidis Christos
Принадлежит: Merck Patent GmBH

Compounds of the formula I 2. Compounds according to in which{'sup': '4', 'Rdenotes H, OA′, Hal or A′,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.3. Compounds according to claim 1 , in which{'sub': '2', 'sup': '5', 'A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein one or two non-adjacent CH- and/or CH-groups may be replaced by N- and/or O-atoms and wherein 1-7 H-atoms may be replaced by R,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.4. Compounds according to claim 1 , in which{'sup': 3', '3', '3', '3, 'sub': 2', '2', 'p', '2', 'p', '2, 'Ar denotes phenyl, which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, CN, CON(R), [C(R)]OA, [C(R)]COOR, A, Cyc and/or OCHCyc,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.5. Compounds according to claim 1 , in which{'sup': '1', 'Ardenotes phenyl or naphthyl,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.6. Compounds according to claim 1 , in which{'sup': 3', '3', '3', '3', '1', '3, 'sub': 2', 'p', '2', 'n', '2', '2', '2', 'n, 'Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, [C(R)]OA′, [C(R)]N(R), CON(R), Het, A, [C(R)]CN and/or ═O,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.7. Compounds according to claim 1 , in which{'sup': '1', 'Hetdenotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which is unsubstituted or mono- or disubstituted by Hal, A and/or ═O,'}and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures ...

Подробнее
Номер записи: 97
31-07-2014 дата публикации

ANTIBACTERIAL IMIDAZOLIUM COMPOUND AND ANTIBACTERIAL PHOTOCURABLE THIOL-ENE COMPOSITIONS COMPRISING THE SAME, AND ANTIBACTERIAL POLYMER COATINS PREPARED THEREFROM

Номер: US20140212374A1
Автор: AHN Kwang Duk, Kim Man Ho, KIM Mirinae
Принадлежит: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

An antibacterial imidazolium compound, a photocurable coating composition, and an antibacterial coating film includes a compound represented by Chemical Formula 1 shown below or derivatives thereof. 3. The antibacterial imidazolium compound of claim 1 , wherein x is an integer selected from 10 to 20.4. A photocurable coating composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '1 to 50 mol % of the antibacterial imidazolium compound according to ;'}20 to 50 mol % of thiol compound including 1 to 4 thiol groups;20 to 50 mol % of ene compound including carbon-carbon double bond; and0.1 to 10 mol % of photoinitiator.5. The photocurable coating composition of claim 4 , wherein the photocurable coating composition is liquid phase having viscosity ranging from 50 to 3000 cPs at 25° C.6. The photocurable coating composition of claim 4 , wherein the antibacterial imidazolium compound includes any one selected from the group consisting of 1-allyl-3-dodecylimidazolium salt claim 4 , 1-dodecyl-3-4-vinylbenzyl)imidazolium salt claim 4 , and a combination thereof.7. The photocurable coating composition of claim 4 , wherein a sulfur-carbon bond is formed during a photocuring process.10. The method of claim 9 , wherein the reaction comprises processes of claim 9 ,dissolving the compound represented by Chemical Formula 3 in a solvent,mixing the dissolved compound represented by Chemical Formula 3 with the compound represented by Chemical Formula 4,reacting the mixture at a temperature ranging from 60 to 70° C. for 12 to 14 hours, andobtaining an antibacterial imidazolium compound represented by Chemical Formula 1. Pursuant to 35 U.S.C. §119(a), this application claims the benefit of earlier filing date and right of priority to Korean Application No. 10-2013-0009528, filed on Jan. 28, 2013, the contents of which is incorporated by reference herein in its entirety.1. Field of the InventionThe present disclosure relates to an antibacterial imidazolium compound with ...

Подробнее
Номер записи: 98
11-05-2017 дата публикации

PENTAARYLBIIMIDAZOLE COMPOUND AND PRODUCTION METHOD FOR SAID COMPOUND

Номер: US20170130124A1
Автор: ABE Jiro, SUGA Takayoshi, TAMASHITA Hiroaki, TSUTIYA Kazuhiko
Принадлежит: Kanto Kagaku Kabushiki Kaisha

In order to address the problems of conventional photochromic compounds, which are the insufficient coloring/discoloring speed and durability exhibited thereby and the large number of production steps, the present invention provides a photochromic compound that exhibits a high speed coloring/discoloring reaction and high durability while it is able to be synthesized in low cost, and that has industrial applicability. The compound of the present invention is characterized by the insertion of a diarylimidazolyl radical into the ortho position of an aryl group. The compound exhibits photochromic properties, and achieves a photochromic compound having both a high speed color switching reaction and high durability. Furthermore low cost synthesis is possible, and the photochromic compound has industrial applicability. 2. The compound as claimed in claim 1 , wherein the structure of a diarylimidazole moiety at one side and the structure of a diarylimidazole moiety at the other side are different and asymmetric to each other.3. The compound as claimed in claim 1 , wherein each substituent Rto Ris substituent selected one or more from the group consisting of: hydrogen claim 1 , methyl group claim 1 , methoxy group claim 1 , nitro group and cyano group.4. A photochromic material comprising the compound as claimed in .5. A solvent comprising the compound as claimed in .6. A resin comprising the compound as claimed in .8. The compound as claimed in claim 2 , wherein each substituent Rto Ris substituent selected one or more from the group consisting of: hydrogen claim 2 , methyl group claim 2 , methoxy group claim 2 , nitro group and cyano group.9. A photochromic material comprising the compound as claimed in .10. A solvent comprising the compound as claimed in .11. A resin comprising the compound as claimed in .13. A photochromic material comprising the compound as claimed in .14. A solvent comprising the compound as claimed in .15. A resin comprising the compound as claimed in ...

Подробнее
Номер записи: 99
11-05-2017 дата публикации

IONIC LIQUID, LUBRICANT, AND MAGNETIC RECORDING MEDIUM

Номер: US20170130156A1
Автор: Hatsuda Kouki, ITO Makiya, Kondo Hirofumi, Tano Nobuo, WATANABE Masayoshi, Yun KyungSung
Принадлежит: DEXERIALS CORPORATION

A lubricant including: an ionic liquid, which includes a conjugate acid (B) and a conjugate base (X), and is protic, wherein the ionic liquid is represented by the following general formula (1), and wherein the conjugate base is a conjugate base of sulfonic acid, a conjugate base of sulfonimide, or a conjugate base of trisulfonylmethide: 3. A magnetic recording medium comprising:a non-magnetic support;a magnetic layer on the non-magnetic support; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the lubricant according to on the magnetic layer.'} The present invention relates to a protic ionic liquid, a lubricant containing the ionic liquid, and a magnetic recording medium using the lubricant.Conventionally, in a thin film magnetic recording medium, a lubricant is applied onto a surface of a magnetic layer for the purpose of reducing frictions between a magnetic head and the surface of the magnetic recording medium, or reducing abrasion. In order to avoid adhesion, such as sticktion, an actual film thickness of the lubricant is of a molecular order. Accordingly, it is not exaggeration to say that the most important thing for a thin film magnetic recording medium is to select a lubricant having excellent abrasion resistance in any environment.During a life of a magnetic recording medium, it is important that a lubricant is present on a surface of the medium without causing desorption, spin-off, and chemical deteriorations. Making the lubricant present on a surface of a medium is more difficult, as the surface of the thin film magnetic recording medium is smoother. This is because the thin film magnetic recording medium does not have an ability of replenishing a lubricant as with a coating-type magnetic recording medium.In the case where an adhesion force between a lubricant and a protective film disposed at a surface of a magnetic layer is weak, moreover, a film thickness of the lubricant is reduced during heating or sliding hence accelerating abrasion. Therefore ...

Подробнее
Номер записи: 100